Efficacy, Safety, and Tolerability of  
Bictegravir/Emtricitabine/ Tenofovir Alafenamide in Adults 
with HIV -HBV Coinfection  
(BEST -HBV)   
 
Protocol Number : HP-00083844  
NCT # 03797014  
Principal Investigator s:  
Joel V. Chua, MD  
Institute  of Human  Virology    
University  of Maryland  School  of Medicine  
725 West  Lombard  Street ,  
Baltimore,  MD 21201   
Tel. (410)  706-5704  
Fax (410)  706-3243  
Co-Investigator s:  
Helena Kwakwa, MD  
Philadelphia Department of Public Health  
Philadelphia, PA  
 
Funded by:  Gilead Sciences Inc.,  Foster City, CA  
Protocol Version: 4 .0 
March  16, 2021  
 
 
CONFIDENTIAL  
The information  contained  in this protocol  is confidential and is intended for the use of the clinical 
investigators and their  study  staff.   The information  in this document  is the property  of Institute of 
Human Virology, and may  not be disclosed  unless  federal  or state law or regulations  require  such 
disclosure.    This information  may  be disclosed  only  to those  persons  involved  in the study  who  
have  a need  to know,  with  the obligation  not to further  disseminate  this information.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  2 
 PROTOCOL  SYNOPSIS  
Title: Efficacy, Safety, and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide in 
Adults with HIV -HBV Coinfection.  
Short Title: BEST -HBV  
Disease: Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfection.  
Primary Objective:  
 To eval uate the efficacy of fixed dosed combination ( FDC) bictegravir/emtricitabine/ 
tenofovir alafenamide ( B/F/TAF)  in adult subjects coinfected with HIV -1 and HBV , as 
determined by HIV-1 RNA <50 copies/mL at Week 24 by US FDA Snapshot Algorithm and/or  
HBV DNA <29 IU/mL at W eek 24 by missing = failure method.  
Secondary Objectives:  
 Evaluate the safety and tolerability of FDC B/F/TAF in HIV -HBV coinfected subjects.  
 Evaluate the efficacy of FDC  B/F/TAF in adult subjects coinfected with HIV -1 and HBV , as 
determined by HIV-1 RNA <50 copies/mL  at Week 48 by FDA Snapshot Algorithm.  
 Evaluate the efficacy of FDC  B/F/TAF in adult subjects coinfected with HIV -1 and HBV , as 
determined by HBV DNA <29 IU/m L at Week 48 by missing = failure method . 
 Evaluate the efficacy of FDC  B/F/TAF in adult subjects coinfected with HIV -1 and HBV , as 
determined by improvement in CD4 count, ALT normalization, HBeAg loss, HBsAg loss, and 
improvement in Fibro Scan test scores f rom baseline to Week 24 and Week 48.  
 
Primary Endpoints : 
 Proportion of subjects with HIV-1 RNA <50 copies/mL at Week 24 by FDA Snapshot 
Algorithm.  
 Proportion of subjects with HBV DNA <29 IU/mL at Week 24 by missing = failure method.  
Secondary Endpoints : 
 Proportion of subjects with HIV -1 RNA <50 copies/mL at Week 48 by FDA Snapshot 
Algorithm.  
 Proportion of subjects with HBV DNA <29 IU/mL at Week 48 by missing = failure method.  
 Assessment of the safety and tolerability of the FDC B/F/TAF  in HIV -HBV coinfected subjects 
as measured by the proportion of subjects who discontinue study medications due to AE.  
 Change from baseline in CD4 cell count and percentage at Week 24 and at 48.  
 Proportion of subjects with normalized ALT at  Week 24 and Week 48.  
 Proportion of subjects with HBV  e antigen (HBeAg) loss  and seroconversion to anti -HBe at 
Week 24 and Week 48.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  3 
  Proport ion of subjects with HBV  surface antigen (HBsAg) loss and seroconversion to anti-
HBs at Week 24 and Week 48.  
 Change from baseline in Fibroscan  test score at Week 24 and Week 48.  
 
Study Design:  
This is a multi center, open -label phase 4 study to evaluate the efficacy, safety, and tolerability 
of treatment with fixed dosed combination bictegravir/emtricitabine/tenofovir alafenamide in 
adults with HIV -1 and HBV coinfection who are currently on  a stable  antiretroviral regimen  for 
at least 3 months.  Subjects who provide written informed consent and meet all eligibility 
criteria will receive FDC Bictegravir 50 mg/Emtricitabine 200 mg/tenofovir alafenamide 25 mg 
(B/F/TAF) administered orally, once daily, without regard to food.  Enrolled subjects will be 
followed up for 48 weeks.  
 
 Target Population: Adults with HIV/HBV coinfection currently on stable antiretroviral regimen 
for at least 3 months.  
Phase of Development: Phase 4 . 
Duration of Treatment:  48 weeks . 
Estimated sample size : 60 participants . 
Estimated number needed to screen to achieve sample size:  75. 
Estimated Accrual Period: 12 months . 
 Inclusion Criteria:  
 Age 18 years or older at enrollment . 
 Documented HIV -1 infection and currently on a stable regimen for at least 3 months prior to 
enrollment . 
 No known history of resistance to tenofo vir alafenamide (TAF), emtricitabine (FTC), or 
Bictegravir (BIC)  except M184V  and M184I .  Those with M184V  or M184I  mutations  will be 
allowed to enroll in the study.  
 Documented chronic HBV  infection, based on any of the following:  

BEST -HBV Protocol Version 4.0: March  16, 202 1  4 
 a. Positive HBsAg result or nucleic acid test for HBV DNA (including qualitative, 
quantitative, and genotype testing) or positive HBeAg on two occasions at least 6 
months apart (any combination of these tests performed 6 months apart is 
acceptable); or  
b. Negative immunoglobulin M (IgM)  antibodies to HBV core antigen (anti- HBc IgM) 
AND a positive results on one of the following tests: HBsAg, HBeAg, or nucleic acid test for HBV DNA (including qualitative, quantitative, and genotype testing) prior to 
or at screening.  
 No current or prior regimen containing three  active anti- HBV agents ( drugs active against 
HBV includes lamivudine [3TC], adefovir [ADV], entecavir [ETV], emtrici tabine [FTC], 
tenofovir disoproxil fumarate [TDF], and tenofovir alafenamide [TAF] ). 
 Must have a primary care provider(s) for medical management . 
 Females of childbearing potential must agree to utilize protocol recommended highly 
effective contraceptive me thods or be non -heterosexually active or practice sexual 
abstinence (as defined in Appendix  F
) from screening and throughout the duration of the 
study.  Female subjects who utilize hormonal contraceptive as one of their bir th control 
methods must have used the same method for at least 3 months prior to study drug dosing.  
 Male subjects must be willing to abstain from heterosexual intercourse or use a condom throughout the study period.  
 Stated willingness to comply with all study procedures and availability for the duration of the study.  
 Written informed consent must be obtained before any study procedure is performed.  
Exclusion Criteria:  
 Women  who are pregnant or breastfeeding . 
 Any known allergies to any of the components of B/F/TAF . 
 Treatment with another investigational drug within three months of enrollment.  
 Abnormal hematological and biochemical parameters at screening, including:  
a. Absolute neutrophil count (ANC) < 750 cells/mm
3. 
b. Platelets < 50,000/mm3. 
c. Hemogl obin < 8.5 g/dL . 
d. AST or ALT of > 5 times upper limit of normal (ULN ). 
e. Estimated GFR < 30 mL/min /1.73 m2. 
f. Total  bilirubin > 1.5 times ULN.  
 Previous or  current history of malignancy, other than  cutaneous Kaposi’s sarcoma, basal cell 
carcinoma, or resected, n on-invasive cutaneous squamous cell carcinoma.   Note: Those 
with a history of malignancy who are in remission for two or more years may be included in 
the study.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  5 
  An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to 
scree ning . 
 Subjects experiencing decompensated cirrhosis (e.g. ascites, encephalopathy, or variceal bleeding) . 
 Acute hepatitis in the 30 days prior to study entry . 
 Active tuberculosis infection . 
 Subjects receiving ongoing therapy with any  medications contraindicated for co -
administration with B/F/TAF FDC, including but not limited to  the following medications in 
the table below:  
Drug Class  Prohibited Agents# 
Antiarrhythmic Agent  Dofetilide  
Anticonvulsants  Phenobarbital, Phenytoin, Carbamazepine, Oxcarbamazepine  
Antimycobacterials  Rifampin, Rifapentine , rifabutin  
GI Motility Agents  Cisapride  
Herbal/Natural Supplements  St. John’s Wort, Echinacea  
Miscellaneous agents  Mitotane  
# Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for 
the duration of the study.  
 Current alcohol or substance use that in the opinion of the investigator may interfere with 
subject study compliance  
 Any other clinical conditions that in the opinion of the investigator would make the subject unsuitable for the study or unable to comply with the dosing requirements  
Sample Size Justification & Statistical Analysis:  
The primary analysis endpoint to evaluate treatment efficacy  used to compute the sample size  
is the observed HIV -1 viral suppression rate.  A true suppression rate at Week 24 of at least 91% 
would be considered active in this patient population.  An exact binomial test with a 0 .05 type I 
error rate will have 84% power to detect the difference between the null hypothesis proportion (number of suppressed/total number treated) of 0.773 (based on published results) and the 
research hypothesis proportion of 0.910 (our educated guess on the desired rate of success) when the sample size is 6 0.  
 
  
BEST -HBV Protocol Version 4.0: March  16, 202 1  6 
 TABLE OF C ONTENTS  
PROTOCOL SYNOPSIS  ...................................................................................................................... 2 
LIST OF ABBREVIATIONS  ................................................................................................................. 9 
1 INTROD UCTION  ..................................................................................................................... 12 
1.1 Background & Scientific Rationale  ................................................................................. 12 
1.1.1  Tenofovir alafenamide in HIV -HBV Coinfection  ...................................................... 12 
1.1.2  Bictegravir: New HIV -1 Integrase Strand Transfer Inhibitor  ................................... 13 
1.2 Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)  ........................................ 14 
1.2.1  Description  .............................................................................................................. 14 
1.2.2  Nonclinical Toxicology and Pharmacology  ............................................................. 14 
1.2.3  Clinical Pharmacology  ............................................................................................. 15 
1.2.4  Clinical Studies on Bictegravir/Emtricitabine/Tenofovir Alafenamide  ................... 18 
1.3 B/F/TAF in HIV -HBV Coinfection & Study Hypothesis  .................................................... 18 
1.4 Risk and Benefit Assessments  ........................................................................................ 18 
1.4.1  Risk of using B/F/TAF (BIKTARVY®)  ......................................................................... 18 
1.4.2  Risk of Fibroscan Test .............................................................................................. 20 
1.4.3  Risk of Blood Draw  .................................................................................................. 20 
1.4.4  Risk of Electrocardiogram (ECG)  ............................................................................. 21 
1.4.5  Risk of Allergic Reactions  ........................................................................................ 21 
1.4.6  Risk of Loss of Confidentiality  ................................................................................. 21 
1.4.7  Unexpected Risk and Discomforts  .......................................................................... 21 
1.4.8  Potential Benefits  .................................................................................................... 21 
2 OBJECTIVES  ............................................................................................................................ 22 
2.1 Primary Objective  ........................................................................................................... 22 
2.2 Secondary Objectives  ..................................................................................................... 22 
2.3 Exploratory Objectives  ................................................................................................... 22 
2.4 Primary Endpoints  .......................................................................................................... 22 
2.5 Secondary Endpoints  ...................................................................................................... 22 
2.6 Exploratory Endpoints  .................................................................................................... 23 
3 INVESTIGATIONAL PLAN  ........................................................................................................ 23 
3.1 Summary of Study Design  .............................................................................................. 23 
3.2 Study Procedures  ........................................................................................................... 24 
3.2.1  Pretreatment Assessments ..................................................................................... 24 
3.2.2  Day 1 Assessments  .................................................................................................. 25 
3.2.3  Treatment Assessments  .......................................................................................... 26 
3.2.4  Early Study Drug Discontinuation Assessments  ..................................................... 27 
3.2.5  Criteria for Discontinuation of Study Treatment  .................................................... 28 
3.2.6  End of Study  ............................................................................................................ 28 
3.2.7  Post Study Care  ....................................................................................................... 28 
BEST -HBV Protocol Version 4.0: March  16, 202 1  7 
 3.2.8  Virologic Failure  ...................................................................................................... 29 
3.2.9 Management of Virologic Rebound  ........................................................................ 29 
4 DISCUSSION OF DESIGN  ......................................................................................................... 32 
5 STUDY POPULATION  .............................................................................................................. 33 
5.1 Number  of Subjects and Subject Selection  .................................................................... 33 
5.2 Inclusion Criteria  ............................................................................................................ 33 
5.3 Exclusion Criteria  ............................................................................................................ 34 
6 STUDY INTERVENTION  ........................................................................................................... 35 
6.1 Study Assignment  ........................................................................................................... 35 
6.2 Method of Assignment to Study Intervention  ............................................................... 35 
6.3 Study Drug, Materials, and Supplies  .............................................................................. 35 
6.3.1  Formulation, Packaging, and Labeling  .................................................................... 35 
6.3.2  Storage Handling and Preparation .......................................................................... 36 
6.3.3  Final Disposition of Clinical Supplies  ....................................................................... 36 
6.4 Dosage Administration  ................................................................................................... 37 
6.5 Blinding  ........................................................................................................................... 37 
6.6 Concomitant Medications  .............................................................................................. 37 
7 ADVERSE EVENT AND TOXICITY MANAGEMENT  ................................................................... 38 
7.1 Adverse Events  ............................................................................................................... 38 
7.1.1  Definition of AE  ....................................................................................................... 38 
7.1.2  Reporting Procedures for All Adverse Events  ......................................................... 39 
7.1.3  Adverse Events Severity  .......................................................................................... 40 
7.1.4  Adverse Event Relationship to Study Drug  ............................................................. 40 
7.1.5  Adverse Event Expectedness  .................................................................................. 40 
7.2 Serious Adverse Events  .................................................................................................. 41 
7.2.1 Definition of SAE  ..................................................................................................... 41 
7.2.2  Reporting of SAE  ..................................................................................................... 41 
7.3 Laboratory Tests  ............................................................................................................. 42 
7.4 Repo rting of Events to Participants  ............................................................................... 42 
7.5 Reporting of Pregnancy  .................................................................................................. 42 
7.6 Toxicity Management  ..................................................................................................... 43 
7.6.1 Grade 1 and 2 Laboratory Abnormality or Clinical Event  ....................................... 43 
7.6.2  Grade 3 Laboratory Abnormality or Clinical Event  ................................................. 43 
7.6.3  Grade 4 Laboratory Abnormality or Clinical Event  ................................................. 43 
7.6.4  On-Treatment ALT Flare and Exacerbation of Hepatitis B Management  ............... 44 
7.6.5  On-Treatment Hepatitis C Management  ................................................................ 45 
7.6.6  On-Treatment Hepatitis D Management  ................................................................ 45 
8 QUALITY CONTROL AND QUALITY ASSURANCE  .................................................................... 46 
9 STATISTICAL CONSIDERATIONS  ............................................................................................. 47 
9.1 General Consideration & Populations for Analyses  ....................................................... 47 
9.2 Sample Size Determination  ............................................................................................ 47 
BEST -HBV Protocol Version 4.0: March  16, 202 1  8 
 9.2.1  Analysis Objectives  .................................................................................................  47 
9.2.2  Analysis of the Primary Efficacy Endpoints  ............................................................. 48 
9.2.3  Analysis of the Secondary Endpoints  ...................................................................... 49 
9.2.4  Safety Analyses  ....................................................................................................... 49 
9.2.5  Baseline Descriptive Statistics ................................................................................. 50 
9.2.6  Planned Interim Analyses  ....................................................................................... 50 
9.2.7  Subgroup Analyses  .................................................................................................. 50 
9.2.8  Exploratory Analyses  ............................................................................................... 50 
10 ADMINISTRATIVE, ETHICAL, AND REGULATORY CONSIDERATIONS  .................................. 51 
10.1  Informed Consent Process  ............................................................................................. 51 
10.2  Study Discontinuation and Closure  ................................................................................ 51 
10.3  Confidentiality and Privacy  ............................................................................................ 52 
10.4  Future Use of Stored Specimens and Data  .................................................................... 53 
10.5  Key Roles and Study Governance  ................................................................................... 53 
10.6  SAFETY OVERSIGHT  ........................................................................................................ 53 
10.7  Clinical Monitoring  ......................................................................................................... 54 
10.8  Data Handling and Record Keeping ................................................................................ 54 
10.8.1  Data Collection and Management Responsibilities  ................................................ 54 
10.8.2  Study Records Retention  ........................................................................................ 54 
10.9  Protocol Deviation  .......................................................................................................... 55 
10.10  Publication and Data Sharing Policy  ............................................................................... 55 
10.11  Conflict of Interest Policy  ............................................................................................... 55 
11 REFERENCES  ....................................................................................................................... 56 
APPENDIX A.  SCHEDULE OF ACTIVITIES  ....................................................................................... 59 
APPENDIX B.  PROTOCOL AMENDMENT HISTORY  ........................................................................ 61 
APPENDIX C.  MANAGEMENT OF CLINICAL & LABORATORY AEs  ................................................. 62 
APPENDIX D.  MANAGEMENT OF ON -TREATMENT ALT FLARES  .................................................. 63 
APPENDIX E.  DEFINITION OF STAGE 3 OPPORTUNISTIC ILLNESS IN HIV  ..................................... 64 
APPENDIX  F.  DEFINITION OF CHILDBEARING POTENTIAL, CONTRACTIVE REQUIREMENTS & 
PREGNANCY PRECAUTIONS  .......................................................................................................... 65 
 
 
   
BEST -HBV Protocol Version 4.0: March  16, 202 1  9 
 LIST  OF ABBREVIATIONS  
ABBREVIATIONS  DEFINITIONS  
3TC Lami vudine  
ABC Abacavir  
ADV  Adefovir  
AE Adverse event  
ALT Alanine aminotransferase  
ANC  Absolute neutrophil count  
Anti-HBc (or HBcAb)  Hepatitis B core antibody  
Anti-HBe (or HBeAb)  Hepatitis B e antibody  
Anti-HBs (or HBsAb)  Hepatitis B surface antibody  
APR Antiretroviral Pregnancy Registry  
AST Aspartate aminotransferase  
AUC  Area under the curve  
B/F/TAF  Bictegravir/emtricitabine/tenofovir alafenamide  
BP Blood pressure  
BIC Bictegravir  
BRCP  Breast cancer resistance protein  
c Cobicistat (e.g., as component of EVG/c/FTC/TAF)  
CBC Complete blood count  
CFR Clinical Research Unit  
CI Confidence Interval  
Cmax Maximum concentration of a drug achieved after dosing  
CMP  Comprehensive metabolic panel  
CRU  Clinical Research Unit  
CYP Cytochrome P450 enzyme  
DAIDS  Division of Acquired Immune Deficiency Syndrome  
DDI Drug -drug interaction  
DNA  Deoxyribonucleic acid  
DOH  Department of Health  
DTG  Dolutegravir  
ECG Electrocardiogram  
EVG Elvitegravir  
FDA (US) Food and Drug Administration  
FDC Fixed dose combination  
FSH Follicle stimulating hormone  
FTC Emtricitabine  
GCP Good Clinical Practice  
HbA1c  Hemoglobin A1c  
HBcrAg  Hepatitis B core related antigen  
BEST -HBV Protocol Version 4.0: March  16, 202 1  10 
 HBeAg  Hepatitis B e antigen  
HBsAg  Hepatitis B surface antigen  
HBV  Hepatitis B virus  
hCG Human chorionic gonadotropin  
HCV  Hepatitis C virus  
HDPE  High density polyethylene  
HDV  Hepatitis D virus  
HIPA A Health Insurance Portability and Accountability Act  
HIV Human immunodeficiency virus  
HLA Human leukocyte antigen  
hsCRP  High sensitivity C -reactive protein  
ICF Informed consent form  
ICH International Conference on Harmonisation  
IgM Immunoglobulin M  
IHV Institute of Human Virology  
INR International normalized ratio  
INSTI  Integrase stand transfer inhibitor  
IRB Institutional Review Board  
IU International units  
MATE  Multidrug and toxin extrusion transporter  
mL Milliliter  
N Number  
NCT National Clinical Trial  
NNRTI  Non -nucleoside reverse transcriptase inhibitor  
NRTI  Nucleos(t)ide reverse transcriptase inhibitor  
OCT Organic cation transporter  
OHRP  Office for Human Research Protection  
P Pulse rate  
PBMC  Peripheral blood mononuclear cells  
PCR Polymerase chain reaction  
P-gp P-glycoprotein  
PI Principal Investigator  
PT Prothrombin time  
PTT Partial thromboplastin time  
PVE (Gilead Sciences) Pharmacovigilance and Epidemiology  
QA Quality assurance  
QC Quality control  
QD Once daily (i.e. quaque die ) 
R Respiratory rate  
RAL Raltegravir  
RAV Resistance associated variant  
RBC Red blood cell (erythrocyte) count  
BEST -HBV Protocol Version 4.0: March  16, 202 1  11 
 RHD  Recommended human dose  
RNA  Ribonucleic acid  
SAE Serious adverse event  
SAR Suspected adverse reaction  
SC Study coordinator  
SMC  Safety Monitoring Committee  
T Temperature  
t1/2 Half-life 
tmax Time after administration of a drug when the maximum 
plasma concentration is reached  
TAF Tenofovir alafenamide  
TDF Tenofovir disoproxil fumarate  
UGT  UDP -glucuronosyltransferase  
ULN  Upper limit of normal  
U.S. United States  
VL Viral load  
WBC  White blood cell count  
WOCP  Woman of childbearing potential  
Wt Weight  
 
           
BEST -HBV Protocol Version 4.0: March  16, 202 1  12 
 1 INTRODUCTION  
1.1 Background & Scientific Rationale  
Human immunodeficiency virus -1 (HIV -1) infection is a life-threatening and serious disease that 
is of global public health importance.  More than 37 million people worldwide are living  with 
HIV-1 infection.  Of these HIV -1 infected populations, about 5 -20% are also coinfected with the 
hepatitis B  virus (HBV) ( Singh K, et al. 2017 ).  In the United States  (U.S.) , about 10% of people 
with HIV are coinfected with HBV, and  about 20% of all new HBV infections are among gay and 
bisexual men ( CDC Fact Sheet 2017 ).  HIV -HBV coinfection has been associated with a higher  
risk of morbidity and mortality , especially with regard to accelerated liver disease progression 
leading to hepatic failure, need for liver transplantation, and death  (Colin JF, et al. 1999; Thio CL 
2002) .  In addition, HBV coinfection accelerates  immunol ogic and clinical progression of HIV 
infection as well as increases the risk of hepatotoxicity when combination antiretroviral therapy 
(ART) are used (Sun HY et al. 2014 ).  Nevertheless, the a vailability of HBV -active ART  regimens 
has significantly improve d the outcome of the HIV -HBV coinfected population, leading to longer 
life expectanc ies and lower rates of morbidities.  
The University of Maryla nd Medical System has multiple clinical practices that care for patients 
living with HIV -1 and chronic  HBV .  Close to four thousand patients  infected with HIV -1 are 
under its care.    The estimated prevalence rate of HIV -HBV coinfection in these clinical 
practices are between 2 -3%.  The HIV/HBV target population is predominantly Black or of 
African American herit age (89%) followed by White (9.6%), and close to 80% are  males .  
Approximately 87% are already on tenofovir (either TDF or TAF) based regimen as part of their backbone NRTI.  In addition, majority of these coinfected patients are on integrase inhibitor 
(63.8%), though some are still on NNRTIs (14.5%) and others on various protease inhibitors 
(21.7%).  Of those on integrase inhibitors, two -thirds are on dolutegravir (65.9%), while the rest 
are on either elvitegravir (27.3%) or raltegravir (6.8%).  
1.1.1  Tenofovir alafenamide in HIV -HBV Coinfection  
Tenofovir, in the form of  tenofovir disoproxil fumarate ( TDF) has been one of the mainstay 
agent s for the treatment of chr onic HBV infection.  Tenofovir disoproxil fumarate  has 
demonstrated potency and predictable high lo ng-term efficacy resulting in sustained HBV viral 
suppression with favorable safety profile ( EASL 2017 ).  The durability of tenofovir based therapy 
has been well documented with published data as long as 7 -years showing 99.3% of patients 
(N=427) taking TDF  maintaining viral suppression.  In this publication by Dr. Maria Buti and 
colleagues, 80% had ALT normalization, and close to 12% of HBeAg -positive chronic HBV  
subjects had HBsAg loss ( Buti M et al. 2015 ).  Long -term therapy with TDF was also associated 
BEST -HBV Protocol Version 4.0: March  16, 202 1  13 
 with regression of fibrosis in up to 80% by year 5 ( Marcellin P et al. 2013 ).  In addition, no 
resistance to TDF was detected in these multi -year studies ( Buti M et al. 2015 ).   The lack of 
resistance -associated variants (RAV) developing during TDF therapy has be thought to be 
related to several possible factors including: (1) the high binding affinity of tenofovir to YMDD 
(the HBV reverse transcriptase target); (2) higher (30 times) dosage of the tenofovir (compare d 
to other anti -HBV drugs such as adefovir) ; and (3) the constrained mutational space due to 
gene overlap in HBV genome ( Van Hemert et al. 2014 ). 
Tenofovir alafenamide (TAF) is a phosphonated prodrug of tenofovir, developed by Gilead Sciences, due to its enhanced plasma stability compared to TDF.  This allows higher levels of the 
active intracellular form of tenofovir diphosphate to concentrate in target cells such as the 
hepatocytes and lymphoid cells, for the treatment of HBV and HIV -1, respectively ( Mukurami E 
et al 2013; Birkus G et al. 20 12).  As it is able to remain mostly intact in the plasma, TAF 
administration is associated with reduced systemic tenofovir exposure compared to TDF, 
resulting in corresponding reduction in renal or bone complications ( Agarwal K et al. 2015 ).  
The efficacy of TAF against chronic HBV infection has been demonstrated in 2  phase III clinical 
trials.  Among HBe antigen negative chronic HBV patients , TAF was found to be non -inferior to 
TDF at 48 weeks with HBV DNA suppression (defined as <29 IU/mL) of 94% vs 93%,  respectively  
(Buti M, et al. 2016 ).  Similarly, among patients with positive HBeAg at baseline, TAF was also 
found to be non -inferior to TDF with HBV suppression rates of 64% versus 67% (p- value not 
significant), respectively ( Chan HLY, et al. 2016 ).  In these studies, TAF had a more favorable 
side effect profile with fewer declines in bone marrow density and smaller change s in renal 
safety parameters compared to TDF at 48 weeks.  Tenofovir alafenamide  has been used as a 
component of elvitegravir/cobicista t/emtricitabine/  tenofovir alafenamide (EVG/c/FTC/TAF) for 
adults with HIV -HBV coinfection in an open -label noncomparative switch study in Study 1249.  
In this study, at 48 weeks of EVG/c/FTC/TAF, 91.7% of the 72 subjects maintained or achieved virologic s uppression (HIV -1 RNA <50 copies/mL and HBV DNA <29 IU/mL) ( Gallant J et al. 
2016).  The seroconversion rate was 2.9% in HBsAg -positive subjects and in 3.9% of HBeAg -
positive subjects.  Those with abnormal ALT at baseline, 40% had ALT normalization.  TAF is a 
major component of the FDC B/F/TAF that is to be investigated in this study.  
1.1.2 Bictegravir: New HIV -1 Integrase Strand Transfer Inhibitor  
Bictegravir (BIC ) is a  recently approved integrase strand transfer inhibitor ( INSTI)  with a longer 
dissociation half -life from wild -type and G140S+Q148H mutant integrase -DNA complexes  in 
vitro  than other INSTI s, including dolutegravir ( DTG ), raltegravir ( RAL), and elvitegravir ( EVG) 
(White K, et al. 2017 ).  Therefore, BIC  is predicted to have a higher  genetic barrier to resistance  
than other integrase inhibitors .  Bictegravir has a more potent antiviral activity against 
BEST -HBV Protocol Version 4.0: March  16, 202 1  14 
 G140S/Q148H integrase variants in vitro  than DTG ( Hightower K, et al. 2011 ).  In addition, BIC 
has a better resistance pr ofile compared to DTG , based upon in vitro data from patient- derived 
clinical isolates  (While K, et al. 2016; Tsiang M, et al. 2016 ).  Bictegravir does not require 
boosting (unlike EVG) and therefore has less drug -drug interaction potential.  Bictegravir is 
currently available only in a fixed -dose combination (FDC) tablet , coformulated  with 
Emtricitabine (FTC ) and tenofovir alafenamide (TAF) , administered  as a one pill, once daily 
regimen , and is given with or without food.  
1.2 Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)  
1.2.1 Description  
Bictegravir/emtricitabine/tenofovir alafenamide is FDA- approve d (approval date February 
2018) fixed dose combination drug regimen under the brand name BIKTARVY® (Gilead Sciences 
Inc.).  It is indicated as a complete regimen for the treatment of HIV -1 infection in adults who 
have no antiretroviral treatment history or to replace the current antiretroviral regimen in 
those who are virologically suppressed (i.e. HIV -1 RNA <50 copies/mL) on a  stable antiretroviral 
regimen ( Biktarvy 2018 ).  Bictegravir/emtricitabine/tenofovir alafenamide  contains an HIV -1 
integrase strand transfer inhibitor, bictegravir, and two HIV -1 nucleos(t)ide analog reverse 
transcriptase inhibitors, tenofovir alafenamide (TAF) and emtricitabine (FTC).  Both TAF and FTC have activity against HBV infection.  B/F/TAF is  a complete regimen that has the potential to 
offer HIV -HBV coinfected patients a simple, once daily regimen containing drug components 
that provides a high ba rrier to resistance against both HIV -1 and HBV.  B/F/TAF does not require 
boosting, and potentially offers an effective and safe alternative to other regimens, without need for human leukocyte antigen ( HLA) testing or close monitoring of renal or bone toxicities.    
1.2.2 Nonclinical Toxicology and Pharmacology  
1.2.2.1  Studies of Carcinogenesis, Mutagenesis, and Impairment of Fertility  
Bictegravir was not carcinogenic in a 6 -month rasH2 transgenic mouse study at doses of up to 
100 mg/kg/day in males and 300 mg/kg/day in females.  BIC was not genotoxic in the reverse 
mutation bacterial test (Ames test), mouse lymphoma or rat micronucleus assays.  BIC did not 
affect fertility, reproductive performance or embryonic viability in male and female rats at 29 times higher exposur es (area under the curve [ AUC ]) than in humans at the recommended dose 
of 50 mg BIC in B/F/TAF ( BIKTARVY ®). (Biktarvy 2018)  
Emtricitabine, in long -term carcinogenicity studies , was found to have no drug -related increases 
in tumor incidence  found in mice at doses up to 750 mg per kg per day (25 times the human 
systemic exposure at the recommended dose of 200 mg per day in B /F/TAF ), or in rats at doses 
up to 600 mg per kg per day (30 times the human systemic exposure at the recommended dose 
BEST -HBV Protocol Version 4.0: March  16, 202 1  15 
 in B/F/TAF).   Emtricitabine  was not genotoxic in the reverse mutation bacterial test (Ames test), 
mouse lymphoma or mouse micronucleus assays.   Emtricitabine  did not affect fertility in male 
rats at approximately 140 times or in male and female mice at app roximately 60 times higher 
exposures (AUC) than in humans given the recommended 200 mg daily dose in BIKTARVY. 
Fertility was normal in the offspring of mice exposed daily from before birth (in utero) through 
sexual maturity at daily exposures (AUC) of approximately 60 times higher than human exposures at the recommended 200 mg daily dose in B/F/TAF ( BIKTARVY ®). (Biktarvy 2018)  
Since tenofovir alafenamide ( TAF)  is rapidly converted to tenofovir and a lower tenofovir 
exposure in rats and mice was observed aft er TAF administration compared to TDF  
administration, carcinogenicity studies were conducted only with TDF.  Long -term oral 
carcinogenicity studies of TDF in mice and rats were carried out at exposures up to 
approximately 10 times (mice) and four times (ra ts) those observed in humans at the 
recommended dose of TDF (300 mg) for HIV -1 infection.  The tenofovir exposure in these 
studies was approximately 151 times (mice) and 51 times (rat) those observed in humans after 
administration of the daily recommended dose of B /F/TAF (BIKTARVY®) .  At the high dose in 
female mice, liver adenomas were increased at tenofovir exposures approximately 10 times 
(300 mg TDF) and 151 times (BIKTARVY® ) the exposure observed in humans. In rats, the study 
was negative for carcinoge nic findings.  Tenofovir alafenamide  was not genotoxic in the reverse 
mutation bacterial test (Ames test), mouse lympho ma or rat micronucleus assays.  There were 
no effects on fertility, mating performance or early embryonic development when TAF was 
administered to male rats at a dose equivalent to 155 times (25 mg TAF) the human dose based 
on body surface area comparisons for 28 days prior to mating and to female rats for 14 days 
prior to mating through Day 7 of gestation.  (Biktarvy 2018)  
1.2.2.2  Animal Toxicology and Pharmacology  
Minimal to slight infiltration of mononuclear cells in the posterior uvea was observed in dogs 
with similar severity after three and nine month administration of TAF; reversibility was seen 
after a three -month recovery period.  No eye toxicity was observed in the dog at systemic 
exposures of seven (TAF) and 14 (tenofovir) times the exposure seen in humans with the 
recommended daily TAF dose in B/F/TAF (BIKTARVY®) . (Biktarvy 2018)  
1.2.3 Clinical Pharmacology  
1.2.3.1  Mechanism of Action  
Bictegravir inhibits the strand transfer activity of HIV -1 integrase (integrase strand transfer 
inhibitor; INSTI), and HIV -1 encoded enzyme that is required for viral replication.  Inhibition of 
BEST -HBV Protocol Version 4.0: March  16, 202 1  16 
 integrase prevents the integration of linear HIV -1 DNA into host geno mic DNA, blocking the 
formation of the HIV -1 provirus and propagation of the virus.  (Biktarvy 2018 ) 
Emtricitabine is a synthetic nucleoside analog of cytidine, and is phosphorylated by cellular 
enzymes to form emtricitabine 5’ -triphosphate.  Emtricitabine 5’-triphosphate inhibits the 
activity of the HIV -1 reverse transcriptase by competing with the natural substrate 
deoxycytidine 5’ -triphosphate and by being incorporated into nascent viral DNA which results in 
chain termination.  Emtricitabine 5’ -triphospha te is a weak inhibitor of mammalian DNA 
polymerase α , β, Ɛ, and mitochondrial DNA polymerase γ. (Biktarvy 2018 ) 
Tenofovir alafenamide is a phosphonamidate prodrug of tenofovir (2′ -deoxyadenosine 
monophosphate analog).  Plasma exposure to TAF allows for permeation into cells and then 
TAF is intracellularly converted to tenofovir through hydrolysis by cathepsin A.  Tenofovir is 
subsequently phosphorylated by cellular kinases to the active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits HIV -1 replication through incorporation into viral 
DNA by the HIV reverse transcriptase, which results in DNA chain -termination. Tenofovir 
dipho sphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial 
DNA polymerase γ and there is no evidence of toxicity to mitochondria in cell culture. (Biktarvy 
2018)  
Tenofovir alafenamide has clinical trial p roven activity against HBV.  Tenofovir alafenamide  as a 
lipophilic cell- permeant compound enters primary hepatocytes by passive diffusion and by the 
hepatic uptake transporters OATP1B1 and OATP1B3.  Tenofovir alafenamide  is then converted 
to tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes.  Intracellular tenofovir is subsequently phosphorylated by cellular kinase to the pharmacologically active metabolite tenofovir diphosphate.  Tenofovir diphosphate inhibits 
HBV replication through incorpora tion into viral DNA by the HBV reverse transcriptase, which 
results in DNA chain termination.  Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerase that include mitochondrial DNA polymerase 
γ and there is no evidence of toxicity to 
mitocho ndria in cell culture. ( Vemlidy 2018)  
1.2.3.2  Pharmacodynamics  
Cardiac electrophysiology studies were conducted in a QT/QTc trial  that enrolled 48 health 
volunteers .  In this study, BIC at doses 1.5 to 6 time  recommended dose did not affect the 
QT/QTc interval and did not prolong the PR interval.  TAF at the recommended dose or at a 
dose 5 times the recommended dose  did not affect the QT/Q Tc interval and did not prolong  the 
PR interval.  The effect of FTC on t he QT interval is not known.  (Biktarvy 2018 ) 
BEST -HBV Protocol Version 4.0: March  16, 202 1  17 
 In studies with healthy subjects, the mean change from baseline in serum creatinine with 
administration of BIC 75 mg (1.5 times the approved recommended dosage) once daily with 
food for 14 days was 0.1 mg per dL on Days 7 and 14 compared to placebo.  BID d id not have 
significant effect on the estimated creatinine clearance or on the actual glomerular filtration rate. (Biktarvy 2018 ) 
1.2.3.3  Pharmacokinetics  
The pharmacokinetic (PK) properties  of B/F/TAF components are summarized in Table 1 -1.  The 
multiple dose PK parameters of BIC, FTC, and TAF based on population pharmacokinetic 
analysis as well as a more complete PK description of the regimen and its components are found in the BIKTARVY U.S. package insert published by Gilead Sciences Inc.  It should be noted 
that the pharmacokinetics of B/F/ TAF have not been evaluated in subjec ts coinfected with 
HBV . 
Table 1 -1: Pharmacokinetic Properties of BIC, FTC, and TAF  
 BIC FTC TAF 
Absorption  
tmax (hours)  
Effect of high fat mean (relative to fasting)  
    AUC ratio  
    Cmax ratio   
2.0 - 4.0 
 
1.24 (1.16, 1.33)  
1.13 (1.06, 1.20)   
1.5 - 2.0 
 
0.96 (0.93, 0.99)  
0.86 (0.78, 0.93)   
0.5 - 2.0 
 
1.63 (1.43, 1.85)  
0.92 (0.73, 1.14)  
Distribution  
% bound to human plasma protein 
Blood -to-plasma ratio   
>99%  
0.64   
<4%  
0.6  
~80%  
1.0 
Elimination  
t1/2 (hours)   
17.3 (14.8, 20.7)   
10.4 (9.0   
0.51 (0.45, 0.62)  
Metabolism  
Metabolic path way(s)   
CYP3A  
UGT1A1   
Not significantly 
metabolized   
Cathepsin A (PBMC)  
CES1  (hepatocytes)  
Excretion  
Major route of elimination  
 
 
% of dose excreted in urine  
% of dose excreted in feces   
Metabolism  
 
 
35%  
60.3%   
Glomerular filtration 
and active tubular 
secretion  
70%  
13.7%   
Metabolism  
 
 
<1%  
31.7%  
The half -life of tenofovir  diphosphate , the active metabolite of TAF, is between 150 -180 hours 
within the hepatocytes.  In vivo, TAF is hydrolyzed within cells to form tenofovir (major 
metabolite), which is phosphorylated to the active metabolite, tenofovir diphosphate.  In vitro 
studies have shown that TAF is metabolized to tenofovir by cathepsin A in PBMCs and 
macrophages, and by carboxylesterase 1 (CES1) in hepatocytes.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  18 
 1.2.4 Clinical Studies on Bictegravir/Emtricitabine/Tenofovir Alafenamide  
Bictegravir/Emtricitabine/tenofovir alafenamide (B/F/TAF) ha s been clinically shown  to be 
highly effective in the treatment of HIV -1 infection based upon two phase 3 treatment -naïve 
trials, the Study 1489 and Study 1490.  In Study 1489 study (Gallant J, et al. 2017 ), N = 631 , 
B/F/TAF demonstrated non -inferiority to DTG /ABC/3TC (VL  ≤ 50 copies/mL  at 48 weeks, 
B/F/TAF 92.4% vs . DTG /ABC/3TC  93.0%, p=0.78).  No treatment emergent resistance developed 
in either treatment arm.   This study excluded HIV -HBV coinfect ed patients .  In S tudy 1490 ( Sax 
PE, et al. 2017 ), N = 742 , B/F/TAF demonstrated non -inferiority to DTG + TAF/FTC (VL  ≤ 50 
copies/mL  at 48 weeks, BIC 89% vs DTG 93%, p=0.12).  There were  no treatment emergent 
resistance in either  arm.   In contrast to the previous study, HBV  coinfection were allowed to be 
enrolled in Study 1490.  Nevertheless, of the 320 patients in the study  who received B/F/TAF, 
only eight (2%) subjects were coinfected with HBV (Sax PE, et al. 2017 ).  
1.3 B/F/TAF in HIV -HBV Coinfection & Study Hypothesis  
Though  the safety and efficacy of B/F/TAF has been well established in the treatment of  HIV-1 
infection and TAF  has been found to be as efficacious and durable as TDF in the treatment of 
HBV  infection, there is limited data on the use of B/F/TAF in the HIV -HBV coinfected 
subpopulation.  The 2 phase III registration studies (Treatment -naïve Study 1490 and switch 
Study 1878) that allowed HIV/HBV coinfected subjects to be enrolled had a total of only 16 
coinfected subjects who received B/F/TAF (Gallant J, et al. 2017 , Sax PE, et al. 2017 ).  In Study 
1490, all eight coinfected participants who received B/F/ TAF had HIV -1 RNA ≤ 50 copies /mL and 
HBV DNA <29 IU/mL at Week 48  (Rockstroh JK et al. 2018 ).  Likewise, in Study 1878, all eight 
volunteers with HIV -HBV coinfection maintained suppression against both viruses ( Rockstroh JK 
et al. 2018 ).  Thus, there is a need for additional data to further validate the use of B/F/TAF as a 
mainstay regimen in the treatment of HIV -HBV coinfected people.  This study will be conducted 
to obtain real -world data in a larger population to help address this need.  The main hypothesis 
of this study is that fixed -dose combination (FDC) B/F/TAF is safe and efficacious in the  
treatment of adults coinfected with HIV -1 and HBV  virus.  
1.4 Risk and Benefit Assessments  
1.4.1 Risk of using B/F/TAF (BIKTARVY®)  
1.4.1.1  Adverse Events in Clinical Trials  
The most common adverse events reported in at least 5% of subjects in those who have taken 
B/F/TAF ar e diarrhea, nausea, and headache.  The proportion of subjects who discontinued 
treatment with B/F/TAF due to adverse events, regardless of severity was 1%.  The majority 
(87%) of adverse events associated with B/F/TAF were Grade 1.  Table 1 -2 displays the 
BEST -HBV Protocol Version 4.0: March  16, 202 1  19 
 frequency of adverse events greater than or equal to 2% in the two treatment naïve registry 
studies (Study 1489 and study 1490) , attributed to study drug by the investigator . (Biktarvy 
2018)  
Table 1 -2: Adverse React ions (All Grades) Reported in > 2% of HIV Infected Adults with No 
Antiretroviral Treatment History Receiving B/F/TAF in Study 1489 or 1490 (Week 48 Analysis)  
Adverse Reactions  Study 1489  
N=314  Study 1490  
N=325  
Diarrhea  6% 3% 
Nausea  5% 3% 
Headache  5% 4% 
Fatigue  3% 2% 
Abnormal dreams  3% <1%  
Dizziness  2% 2% 
Insomnia  2% 2% 
 
1.4.1.2  Pregnancy and Breastfeeding Risks  
The prevalence of birth defects per 100 live births among HIV -1 infected women with a first 
trimester exposure to any ART is 2.7 (95% confidence interval (CI): 2.4 -3.1), i.e. 255 outcomes 
with defects of 9,336 live births according to the Antiretroviral Pregnancy Registry, January 
2018 interim report ( AP Registry 2018 ).  This prevalence of defects was not significantly 
different from those with an initial exposur e during the 2nd and 3rd trimester, nor was it 
different from non- HIV population based pregnancy registries ( AP Registry 2018).  In the U.S. 
general population, the estimated background risk of major birth defects and miscarriage in 
clinically recognized p regnancies is 2 –4% and 15 –20%, respectively.   
A pregnancy exposure registry (The Antiretroviral Pregnancy Registry or APR)  is being used to 
monitors pregnancy outcomes in women exposed to B/F/TAF during pregnancy.  Currently, 
there is insufficient human da ta on the use of B/F/TAF during pregnancy to inform of drug -
associated risk of birth defects and miscarriage.  Both BIC and TAF use in pregnant women have 
not been evaluated.  There is a limited number of women with use of FTC use during pregnancy 
reported  in the APR with prevalence rates not different from general population ( AP Registry 
2018).  ( Biktarvy 2018 ) 
In animal studies, there is no evidence of adverse reproductive developmental outcomes observed with any of the components of B/F/TAF at exposure t hat were either not maternally 
toxic (rabbits) or greater than (rats and mice) those in humans at the recommended human 
BEST -HBV Protocol Version 4.0: March  16, 202 1  20 
 dose (RHD).  During organogenesis, systemic exposures to BIC  were approximately 36 (rats) and 
0.6 times (rabbits), to FTC were approximately 60 (mice) and 108 times (rabbits), and to TAF 
were approximately two  (rats) and 78 times (rabbits) the exposure at the recommended human 
dose of B/F/TAF. ( Biktarvy 2018 ) 
The Center for Disease Control and Prevention recommends that HIV -1 infected mothers in the 
U.S. not breastfeed their infants to avoid risking postnatal transmission of HIV -1 infection.  
Nevertheless, it is not known whether B/F/TAF or any of its components are present in human 
breast milk, affects human milk production, or has effects on the breastfeeding infant. ( Biktarvy 
2018)  
As the effects of B/F/TAF on an unborn baby or a nursing infant are not known, care must be 
taken to avoid pregnancy in female su bjects or in female partners of male subjects during this 
study and following completion of study treatment (30 days after completion for women, 14 days after completion for men).  Subjects will be excluded if they  are pregnant, planning to 
become pregnant , or while breast -feeding.  
1.4.2 Risk of FibroS can® Test 
FibroScan ® is a noninvasive diagnostic ultrasound based device used to measure liver scarring, 
or fibrosis, caused by various diseases including HBV .  It provides a non -surgical alternative to 
liver biopsy  to assess liver damage.   
In preparation for this procedure, subjects will be advised not to eat or drink ( excluding  water) 
for at least 3 hours  prior to procedure.  The FibroScan ® test usually takes about 5 -10 minutes.  
During the procedure, the subject will lie supine on his/her back with the right arm raised behind his/her head and the right abdominal area is exposed.  A trained study staff member 
will apply a water -based gel to the skin and place the non- invasive probe over the liver area.  
Fasting prio r to procedure can result in hypoglycemia, lightheadedness or fainting.  During the 
procedure, there is a small but possible risk of localized allergic reaction and irritation related to the water -based lubricating gel as well as discomfort due to position ing while in supine 
position.     
1.4.3 Risk of Blood Draw  
Collecting blood samples from a vein may cause pain, bruising, lightheadedness, fainting, 
bleeding and rarely infection at the site of the needle stick.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  21 
 1.4.4 Risk of Electrocardiogram (ECG)  
After an ECG, subjects may experience mild skin irritation, slight redness or itching where the 
recording patches were placed.  They may also need to have chest hair shaved for the 
procedure.  
1.4.5 Risk of Allergic Reactions  
Allergic reaction is always possible with a drug th at the study participant has never been 
exposed to before.  Serious allergic reactions that can be life -threatening may occur.  Some 
things that happen during any allergic reaction to any type of medication are: rash, difficulty 
breathing, wheezing, sudden  drop in blood pressure, swelling around the mouth, throat, or 
eyes, fast pulse, and/or sweating may occur.  Study participants will be monitored closely for 
any reactions.  
1.4.6 Risk of Loss of Confidentiality  
There is always a potential for the loss of confide ntiality.  This risk will be minimized by keeping 
all study data stored and secured.  Electronic data will be password protected. Private 
information will only be given o ut as listed in the Health Insurance Portability and 
Accountability Act ( HIPAA ) form.  
1.4.7 Unexpected Risk and Discomforts  
There may be risks in this study that are not yet known, or that happens  rarely when subjects 
take these study drugs.  Subjects will be told of any new information that could affect  their 
safety during study participa tion.  
1.4.8 Potential Benefits  
All patients with HIV -1 infection should receive effective antiretroviral therapy.  Selection of 
drugs for HIV -1 patients coinfected with HBV should take into consideration the regimen’s anti -
HBV activity to prevent potentially lif e-threatening hepatitis flares.  B/F/TAF FDC regimen has 
the potential to offer HIV -HBV infected patients a simple, once daily regimen containing drug 
components that provides a high barrier to resist ance against both HIV -1 and HBV.  B/F/TAF  
does not requi re a boosting agent, and offers an effective and safe alternative to other 
regimens, without need for HLA testing or close monitoring of renal or bone toxicities.   In addition, patient participation in this study will contribute to the body of knowledge a bout 
treatment for HIV -HBV coinfection.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  22 
 2 OBJECTIVES  
2.1 Primary Objective  
 To evaluate the efficacy of fixed dosed combination (FDC) bictegravir/emtricitabine/ 
tenofovir alafenamide (B/F/TAF) in adult subjects coinfected with HIV -1 and HBV , as 
determined by HIV-1 RNA <50 copies/mL at Week 24 by US FDA Snapshot Algorithm and/or  
HBV DNA <29 IU/mL at W eek 24 by missing = failure method.  
2.2  Secondary Objectives  
 Evaluate the safety and tolerability of FDC B/F/TAF in HIV -HBV coinfected subjects.  
 Evaluate the efficacy of FDC B/F/TAF in adult subjects coinfected with HIV -1 and HBV , as 
determined by HIV -1 RNA <50 copies/mL at Week 48 by FDA Snapshot Algorithm.  
 Evaluate the efficacy of FDC B/F/TAF in adult subjects coinfected with HIV -1 and HBV , as 
determined by HBV DNA <29 IU/mL at Week 48 by missing = failure method.  
 Evaluate the efficacy of FDC B/F/TAF in adult subjects coinfected with HIV -1 and HBV , as 
determined by improvement in CD4 count, ALT normalization, HBeAg loss, HBsAg loss, and 
improvemen t in Fibroscan test scores from baseline to Week 24 and Week 48.  
2.3  Exploratory Objectives  
 Evaluate changes in quantitative HBsAg levels during treatment with FDC B/F/TAF.  
 Evaluate any changes in immune activation  markers  (plasma hsCRP, IL -6, TNF -α, and D-
dimer and cellular HLA- DR+CD38+ CD4 and CD8 T lymphocytes) during treatment with FDC 
B/F/TAF.  
2.4 Primary Endpoints  
 Proportion of subjects with HIV -1 RNA <50 copies/mL at Week 24 by FDA Snapshot 
Algorithm.  
 Proportion of subjects with HBV DNA <29 IU/mL at Wee k 24 by missing = failure method.  
2.5  Secondary Endpoints  
 Proportion of subjects with HIV -1 RNA <50 copies/mL at Week 48 by FDA Snapshot 
Algorithm.  
 Proportion of subjects with HBV DNA <29 IU/mL at Week 48 by missing = failure method.  
 Assessment of the safety and tolerability of the FDC B/F/TAF in HIV -HBV coinfected subjects 
as measured by the proportion of subjects who discontinue study medications due to AE.  
 Change from baseline in CD4 cell count and percentage at Week 24 and at 48.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  23 
  Proportion of subjects with normalized ALT at Week 24 and Week 48.  
 Proportion of subjects with HBV  e antigen (HBeAg) loss and seroconversion to anti- HBe at 
Week 24 and Week 48.  
 Proportion of subjects with HBV  surface antigen (HBsAg) loss and seroconversion to anti-
HBs at Week 24 an d Week 48.  
 Change from baseline in Fibroscan test score at Week 24 and Week 48.  
2.6 Exploratory Endpoints  
 Change from baseline in quantitative HBsAg at Week 24 and Week 48.  
 Assessment of  changes in immune activation markers (plasma hsCRP, IL -6, TNF -α, and D-
dimer and cellular HLA- DR+CD38+ CD4 and CD8 T lymphocytes) during treatment with FDC 
B/F/TAF.  
3 INVESTIGATIONAL  PLAN  
3.1 Summary of Study Design  
This is a multi center, open -label phase 4 study to evaluate the efficacy, safety, and tolerability 
of treatm ent with fixed dosed combination bictegravir/emtricitabine/tenofovir alafenamide in 
adults with HIV -1 an d HBV coinfection  who are currently on a stable antiretroviral regimen  for 
at least 3 months .  Two  sites are planned  to participate: Institute of Human Virology (IHV), 
University of Maryland, Baltimore, MD  and Philadelphia Department of Health (DOH) Clinic .  
Subjects who provide written informed consent and meet all eligibility criteria will receive fixed 
dose combinati on of Bictegravir 50 mg/Emtricitabine 200 mg/tenofovir alafenamide 25 mg 
(B/F/TAF) administered orally  one pill once daily, without regard to food.  Study treatment 
duration for e nrolled subjects will be 48 weeks.  Safety evaluations will consist of advers e 
event, physical examination (including vital signs), and clinical laboratory data.  Efficacy will be 
evaluated by HIV RNA and HBV DNA levels.  
Figure 3 -1. Study Schema  
 

BEST -HBV Protocol Version 4.0: March  16, 202 1  24 
 3.2 Study Procedures  
See also Schedule of Activities ( Appendix  A). 
3.2.1 Pretreatment Assessments  
3.2.1.1  Screening Assessments  (Day  -90 to Day -3)  
The following screening assessments must be done to determine subject eligibility.  Written 
consent will be obtained before conducting any study  procedures.  
 Screen for inclusion/exclusion  (see Section 5 ). 
 Medical History.  
 Complete p hysical examination, including weight, height, and vital signs (blood pressure, 
respiratory rate, heart rate, and temperature).  
 Collect concomitant medication information.  
 12-lead electrocardiogram (ECG).  
 Plasma HIV -1 RNA.  
 Plasma HBV DNA.  
 Quantitative HBsAg level.  
 CD4 cell count.  
 HBV  profile  [HBsAg, HBeAg , anti- HBs, anti- HBe, and anti -HBc both IgM and total] . 
 HCV serology . 
 HDV serology . 
 Complete blood count [hematocrit, hematocrit , erythrocyte count (RBC), white blood 
cell count (WBC), percentage and absolute WBC differential counts, platelet count].  
 Comprehensive metabolic panel [glucose, blood urea nitrogen, creatinine, sodium , 
potassium, chloride, total carbon dioxide, calcium, total protein, albumin, total globulin, 
total bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate 
aminotransferase].  
 Coagulation tests [activated partial thromboplastin time (PTT), prot hrombin time (PT), 
international normalized ratio (INR)].  
 Urinalysis.  
 Serum pregnancy test for women  of childbearing potential (defined as a woman who is 
physiologically capable of becoming pregnant).  
With the exception of the serum pregnancy test, o utside clinical laboratory tests may be 
used for screening if it was done within 90 days of screening.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  25 
 3.2.2 Day 1  Assessments  
Screening tests must be available before the subject is eligible for study participation.  Once 
screening i s completed and the subject meets all eligibility criteria, the subject will ob tain 
baseline evaluations.  Study drug administration may occur after completion of all baseline procedures.  
Before Study Drug Administration:  
 Review eligibility criteria (see Section 5
) and confirm eligibility of subject.  
 Obtain interval medical history . 
 Conduct co mplete physical examination, including weight and vital signs [blood 
pressure (BP), respiratory rate (R), heart rate (HR), and tem perature (T)].  
 Collect concomitant medication information.  
 Plasma HIV -1 RNA  
 Plasma HBV DNA.  
 Quantitative HBsAg level.  
 CD4 cell count.  
 HIV-1 genotype/phenotype, if HIV -1 RNA is ≥ 500 copies/mL . 
 HBV genotype  and resistance assay , if HBV  DNA is ≥ 500 IU/mL . 
 Complete blood count . 
 Comprehensive metabolic panel.  
 Urine pregnancy test for  women  of childbearing potential.  
 FibroScan test  (IHV only) – this test may be conducted within 30 days prior to or on 
the Day 1 Visit.  
 Blood for PAXgene DNA and RNA a nalysis . 
 Blood for storage of plasma, serum, and peripheral blood mononuclear cells (PBMC) 
for future research purposes.  
Study Drug Administration (and Post- Study Drug Assessments) : 
 Administer first dose of B/F/TAF.  
 Dispense study drug supply (remainder of 60 -day supply).  
 Reinforce study drug instruction: subjects are to take one (1)  tablet of B/F/TAF once 
daily upon awakening with at least 8 oz. of plain water, and without regards to food.  
 Dispense Study Drug Diary.  
 Collect adverse event information.  
 Collect concomitant medication information.  
 Instruct subject to bring all study drug s and bottles to each future study visits.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  26 
 3.2.3 Treatment  Assessments  
3.2.3.1  Week 4  and 8 Visits  (± 7 days)  
 Obtain interval medical history.  
 Conduct targeted physical examination (if needed), including weight and vital signs [BP, 
R, HR, T].  
 Collect concomitant medicat ion information.  
 Collect adverse event information.  
 Evaluate Patient Diary and number of used and unused tablets.  
 Plasma HIV -1 RNA.  
 Plasma HBV DNA.  
 Quantitative HBsAg level.  
 Complete blood count.  
 Comprehensive metabolic panel.  
 Urine pregnancy test for wome n of childbearing potential.  
 Blood for storage of plasma, serum, and PBMCs.  
 Dispense study drug supply (30 -day supply  for Week 4; 60 -day supply for Week 8 ). 
 Reinforce study drug instruction: subjects are to take one (1) tablet of B/F/TAF once daily upon aw akening with at least 8 oz. of plain water, and without regards to food.  
 Instruct subject to bring all study drugs and bottles to each future study visits.  
3.2.3.2  Week 12 , 24, and 36 Visits  (± 2 weeks  for Week 12 and Week 36; ± 4 weeks for 
Week 24 ) 
 Obtain interval medical history.  
 Conduct targeted physical examination (if needed), including weight and vital signs [BP, R, HR, T].  
 Collect concomitant medication information.  
 Collect adverse event information.  
 Evaluate Patient Diary and number of used and unused tablets.  
 Plasma HIV -1 RNA.  
 Plasma HBV DNA.  
 Quantitative HBsAg level.  
 CD4 cell count.   
 Complete blood count.  
 Comprehensive metabolic panel.  
 Urine pregnancy test for women  of childbearing potential.  
 Blood for PAXgene RNA analysis.  
 Blood for storage of  plasma, serum, and PBMCs.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  27 
  Dispense study drug supply ( 90-day supply).  
 Reinforce study drug instruction: subjects are to take one (1) tablet of B/F/TAF once 
daily upon awakening with at least 8 oz. of plain water, and without regards to food.  
 Instruct subj ect to bring all study drugs and bottles to each future study visits.  
Additional Week 24 assessments:  
 HBV  profile.  
 FibroScan test  (IHV only).  This test may be done during the Week 24 v isit, or within 2 
weeks (before or after) the scheduled W eek 24 v isit. 
3.2.3.3  Week 48 Visit ( ± 4 weeks ): End -of-Study Assessments  
This describes the end -of-study assessments for all subjects including those who discontinue 
study prematurely.   
 Obtain interval medical history.  
 Conduct complete physical examination , including weight and vital signs [BP, R, HR, T].  
 Collect concomitant medication information.  
 Collect adverse event information.  
 Evaluate Patient Diary and number of used and unused tablets.  
 Plasma HIV -1 RNA.  
 Plasma HBV DNA.  
 Quantitative HBsAg level.  
 CD4 cell count.   
 HIV-1 genotype/phenotype, if HIV -1 RNA is ≥ 500 copies/mL.  
 HBV genotype and resistance assay, if HBV DNA is ≥500 IU/mL.  
 HBV  profile.  
 Complete blood count.  
 Comprehensive metabolic panel.  
 Coagulation tests.  
 Urine pregnancy test for women  of childbearing poten tial. 
 FibroScan test  (IHV only).  This test may be done during the Visit, or within 2 weeks 
(before o r after) the scheduled Week 48 v isit. 
 Blood for PAXgene RNA analysis.  
 Blood for storage of plasma, serum, and PBMCs.  
3.2.4 Early Study Drug Discontinuation  Asses sments  
If the subject discontinues s tudy drug prior to the Week 48 V isit, the subject will be asked to 
return to the clinic within 72 hours of stopping study drugs for the Early Study Drug 
BEST -HBV Protocol Version 4.0: March  16, 202 1  28 
 Discontinuation Visit.  The subject will be asked to continue attending the scheduled study visits 
through Week 48, unless informed consent has been withdrawn.  
At the Early Study Drug Discontinuation Visit, any evaluation showing abnormal results 
indicating that there is a possible or probable causal relationship with the  study drug, will be 
repeated weekly (or as often as deemed prudent by the Investigator) until the abnormality is resolved, returns to Day 1, or is otherwise explained, or subject has withdrawn consent.  
Assessments for the Early Study Drug Discontinuation Visit will follow assessments for Week 48 
Visit (see Section 3.1.3.3
) exce pt for FibroScan test.  A FibroScan test will be done if this Early 
Study Drug Discontinuation Visit is also an End -of-Study Visit.   Additional safe ty labs may be 
done at the discretion of the Investigator.  
3.2.5 Criteria for Discontinuation of Study Treatment  
Study medication may be discontinued in the following instances:  
 Intercurrent illness that would, in the judgment of the Investigator, affect assessm ents 
of clinical status to a significant degree.  Following resolution of intercurrent illness, the 
subject may resume study dosing at the discretion of the Investigator.  
 Unacceptable toxicity, or toxicity that, in the judgment of the Investigator, comprom ises 
the ability to continue study -specific procedures or is considered to not be in the 
subject’s best interest.  
 Lack of efficacy.  
 Subject requests to discontinue for any reason.  
 Subject noncompliance.  
 Pregnancy during the study.  
 Development of active tuberculosis infection.  
 Discontinuation of the study at the request of Gilead, a regulatory agency, or an 
institutional review board (IRB).  
3.2.6 End of Study  
The end of study will be the last patient’s last observation (or visit).  
3.2.7 Post Study Care  
After a subject has completed or terminated their participation in the study, long -term care for 
the subject will remain the responsibility of their primary treating physician.  
 
BEST -HBV Protocol Version 4.0: March  16, 202 1  29 
 3.2.8 Virologic Failure  
HIV-1 virologic failure is defined as virologic rebound or h aving HIV -1 RNA ≥ 50 copies/mL at 
study drug discontinuation, Week 24 , or Week 48.   
HBV virologic failure is defined as virologic rebound or having HBV DNA ≥29 IU/mL at study drug 
discontinuation, Week 24, or Week 48.   Development of tenofovir resistance pl us use of an 
anti-HBV agent (e.g. entecavir) other than the study drug during the treatment period will also 
be considered a HBV virologic failure.  
3.2.9 Management of Virologic Rebound  
Subjects who meet the criteria listed below will be considered to have virologic rebound:  
HIV- 1 Virologic Rebound:  
 At any visit, a rebound in HIV -1 RNA ≥50 copies/mL, which is subsequently confirmed at 
the following scheduled or unscheduled visit; OR  
 At any visit, a >1 log 10 increase in HIV -1 RNA from nadir which is subsequently c onfirmed 
at the following scheduled or unscheduled visit.  
Following unconfirmed virologic rebound, subjects will be asked to return to the clinic for a scheduled or unscheduled blood draw (2 to 3 weeks after the date of the original test that 
resulted in H IV-1 RNA virologic rebound) for confirmation of virologic rebound.  If virologic 
rebound is confirmed at the scheduled or unscheduled visit and the HIV -1 RNA is ≥500 
copies/mL, the blood sample from the confirmation test will be the primary sample used for 
HIV-1 genotypic and phenotypic testing.  Subjects with documented non- adherence within 72 
hours of the visit may not be tested for resistance.  Resistance testing will be conducted on a 
case -by-case basis.  Any subject may be discontinued at Investigator’ s discretion.  
If no resistance is detected, the subject may remain on study drug and a repeat HIV -1 RNA 
should be repeated (approximately 2 to 3 weeks after date of test with HIV -1 RNA ≥50 
copies/mL).  Investigator should carefully evaluate the benefits an d risk of remaining on the 
study drug for each individual subject and document this assessment in the medical record.  
Subject who are noncompliant on an ongoing basis will be considered for discontinuation per the Investigator’s discretion.  
For subjects who are off study drug but remain on study, it will be the Investigator’s discretion 
to manage virologic rebound.  
Figure 6 -1 illustrates the algorithm for the management of subjects who meet the criteria for 
HIV-1 virologic rebound.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  30 
 Figure 6 -1: Vi rologic Rebound Schema for HIV -1. 
 
 
 
HBV Virologic Rebound:  
 At any visit, after achieving HBV DNA  <29 IU/mL, a rebound in HBV DNA  ≥29 IU/mL, 
which is subsequently confirmed at the following scheduled or unscheduled visit; OR  
 At any visit, a >1 log 10 increase in HBV DNA from nadir which is subsequently confirmed 
at the following scheduled or unscheduled visit.  
Following unconfirmed v irologic rebound, subjects will be asked to return to the clinic for a 
scheduled or unscheduled blood draw (2 to 3 weeks after the date of the original test that 
resulted in HBV DNA virologic rebound) for confirmation of virologic rebound.  If virologic 
rebound is confirmed at the scheduled or unscheduled visit and the HBV DNA is ≥500 IU/mL, 
the blood sample from the confirmation test will be the primary sample used for HBV genotyping and drug resistance assay .  Subjects with documented non- adherence within  72 
hours of the visit may not be tested for resistance .  After a subject’s first post baseline 
resistance test, additional testing will be conducted on a case -by-case basis.  Any subject may 
be discontinued at Investigator’s discretion.  
If no resistance is  detected, the subject may remain on study drug and a repeat HBV DNA 
should be repeated (approximately 2 to 3 weeks after date of latest test with HBV DNA ≥29 

BEST -HBV Protocol Version 4.0: March  16, 202 1  31 
 IU/mL).  Investigator should carefully evaluate the benefits and risk of remaining on the study 
drug for each individual subject and document this assessment in the medical record.  
Subject who are noncompliant on an ongoing basis will be considered for discontinuation per the Investigator’s discretion.  
For subjects who are off study drug but remain on study, it will be the Investigator’s discretion 
to manage virologic rebound.  
Figure 6 -2 illustrates the algorithm for the management of subjects who meet the criteria for 
HBV virologic rebound.  
 
*Addition of a “3rd” HBV agent in the setting of tenofovir resistance is considered a HBV virologic failure.  
 
 
 
 

BEST -HBV Protocol Version 4.0: March  16, 202 1  32 
 4 DISCUSSION  OF DESIGN  
This is a multi center, open -label phase 4 study to evaluate the efficacy, safety, and tolerability 
of treatment with fixed dosed combination B/F/TAF in adults with HIV -1 and HBV coinfection.  
This study design allows direct assessment of the safety and efficacy of B/F/TA F in this patient 
population.  
Dose:  B/F/TAF is FDA- approved as a fixed dose combination one pill once daily taken orally 
without regards to food.  The approved regimen contains 50 mg of bictegravir, 200 mg of 
emtricitabine, and 25 mg of tenofovir alafenamide.  Efficacy of this FDC B/F/TAF for HIV -1 
infection has been established based on four double blind, randomized, active control multice nter studies ( two treatment  naïve and two switch studies) with 1206 subjects receiving 
B/F/TAF and combined virologic s uppression rate of 91.8% at Week 48 by FDA Snapshot 
analysis.   In these studies, less than 1% discontinued B/F/TAF due to adverse events.  The  
selected dosing is therefore most appropriate for use in this study.  
Safety Endpoints:  The safety assessments use d in this trial are standard assessments for Phase 
4 studies evaluating the safety of repeated dosing.  
Efficacy Endpoints:  Assessment of quantitative plasma HIV -1 RNA and HBV DNA is the standard 
procedure for determining effectiveness of HIV -1 and HBV  ther apies, respectively.  Both 
primary and secondary efficacy endpoints use both quantitative HIV -1 RNA and HBV DNA levels 
as main assessment measure.  Additional assessments in this trial (e.g . CD4 count, ALT changes, 
FibroScan test) are also standard measure s in trials with HIV -HBV coinfection.  
Length of Assessment:  The efficacy and safety assessments will be evaluated through end of 
study.  This period spans a total of 48 weeks for all subjects.   This duration of assessment is 
standard in studies involving H IV-HBV coinfection with primary and secondary endpoints 
marked at Week 24 and Week 48.  
Eligibility Criteria: This is a phase 4 switch study for subjects with HIV -HBV coinfection.  
Eligibility criteria has been designed to include subjects who in real life may or may not be virally suppressed but would benefit from use of B/F/TAF.  This will allow a broader applicability 
of the study results to a much wider HIV -HBV coinfection population.  In addition, recent 
studies have shown that high efficacy was observed among subjects with baseline M184V or 
M184I  who switched to B/F/TAF with 98% of these subjects achieving HIV -1 RNA <50 copies/mL 
at their last study visit and with no treatment emergent resistance developing ( Andreatta K et 
al 20 19).  
BEST -HBV Protocol Version 4.0: March  16, 202 1  33 
 5 STUDY  POPULATION  
The investigators participating in this study have expertise in the diagnosis and management of 
patients with HIV and HBV .  This study will be conducted in the Institute of Human Virology , 
University of Maryland, Baltimore, MD.  Inve stigators will diagnose subjects with HIV and HBV  
based on history, physical examination, and laboratory studies.   
Participation in this study is voluntary.  The nature of the study will be fully explained to each 
subject during the informed consent proce ss.  The subjects  will have the opportunity to ask 
questions.  An informed consent document will then be signed by the subject and the person 
performing the consent discussion, and retained by the investigator according to Good Clinical 
Practice (GCP).  Th e investigator wi ll retain all documents according to GCP.  A copy of the 
signed informed consent document will be given to the subject.  
Eligibility for enrollment will be based on the results of screening utilizing the following 
inclusion and exclusion criteria.  
5.1 Number of Subjects and Subject Selection  
This study will enroll a pproximately 60 subjects who meet the eligibility criteria.   We estimate 
that up to 75 subjects will need to be screened to achieve this enrollment number.  
5.2 Inclusion Criteria  
Subject s may be included in the study only if they meet all  of the following criteria:  
1. Age 18 years or older at enrollment.  
2. Documented HIV -1 infection and currently on a stable regimen for at least 3 months 
prior to enrollment . 
3. No known history of resistance to TAF , FTC, or BIC  except M184V  and M184I .  Those 
with M184V  or M184I  mutations  will be allowed to enroll in the study.  
4. Documented chronic HBV  infection, based on any of the following:  
a. Positive HBsAg result or nucleic acid t est for HBV DNA (including qualitative, 
quantitative, and genotype testing) or positive HBeAg on two occasions at least 
6 months apart (any combination of these tests performed 6 months apart is 
acceptable); or  
b. Negative immunoglobulin M (IgM) antibodies to  HBV core antigen (anti- HBc 
IgM) AND a positive results on one of the following tests: HBsAg, HBeAg, or nucleic acid test for HBV DNA (including qualitative, quantitative, and genotype 
testing) prior to or at screening.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  34 
 5. No current or prior regimen containing three active anti- HBV agents ( drugs active 
against HBV includes lamivudine [ 3TC], adefovir [ADV], entecavir [ETV], emtricitabine 
[FTC], tenofovir disoproxil fumarate [ TDF], and  tenofovir alafenamide  [TAF]). 
6. Must have a primary care provider(s) for medical management.  
7. Females of childbearing potential must agree to utilize protocol recommended highly 
effective contraceptive methods or be non -heterosexually active or practice sexual 
abstinence (as defined in Appendix F ) from screening and throughout the duration of 
the study.  Female subjects who utilize hormonal contraceptive as one of their birth 
control methods must have used the same method for at least 3 months prior to study drug dosing.  
8.  Male subjects must be willing to abstain from heterosexu al intercourse or use a 
condom throughout the study period.  
9. Stated willingness to comply with all study procedures and availability for the duration of the study.  
10. Written informed consent must be obtained before any study procedure is performed.  
5.3 Exclusion Criteria  
Subject meeting any of the following criteria will not be eligible to participate in the study:  
1. Females who are pregnant or breastfeeding.  
2. Any known allergies to any of the components of B/F/TAF.  
3. Treatment with another investigational drug within three months of enrollment.  
4. Abnormal hematological and biochemical parameters at screening, including:  
a. Absolute neutrophil count (ANC) < 750 cells/mm3. 
b. Platelets < 50,000/mm3. 
c. Hemoglobin < 8.5 g/dL . 
d. AST or ALT of > 5 times upper limit of normal (ULN).  
e. Estimated GFR < 30 mL/min /1.73 m2. 
f. Total bilirubin > 1.5 times ULN . 
5. Previous or current history of malignancy, other than  cutaneous Kaposi’s sarcoma, 
basal cell carcinoma, or resected, non -invasive cutaneous squamous cell carcinoma.   
Note: Those  with a history of malignancy who are in remission for two or more years 
may be included in the study.  
6. An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening.  
7. Subjects experiencing decompensated cirrhosis (e.g. ascites, enc ephalopathy, or 
variceal bleeding) . 
8. Acute hepatitis in the 30 days prior to study entry . 
BEST -HBV Protocol Version 4.0: March  16, 202 1  35 
 9. Active tuberculosis infection . 
10. Subjects receiving ongoing therapy with any  medications  contraindicated for co -
administration with B/F/TAF FDC, including but not limited to the following 
medications in the table below:  
Drug Class  Prohibited Agents# 
Antiarrhythmic Agent  Dofetilide  
Anticonvulsants  Phenobarbital, Phenytoin, Carbamazepine, Oxcarbamazepine  
Antimycobacterials  Rifampin, Rifapentine , Rifabutin  
GI Motility Agents  Cisapride  
Herbal/Natural Supplements  St. John’s Wort, Echinacea  
Miscellaneous Agents  Mitotane  
# Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for 
the duration of the study.  
11. Current alcohol or substance use that in the opinion of the investigator may interfere with subject study compliance . 
12. Any other clinical conditions that in the opinion of the investigator would make the 
subject unsuitable for the study or unable to comply with the dosing requirements.  
6 STUDY  INTERVENTION  
6.1 Study Assignment  
This is an open- label study and all eligible  subjects will receive fixed dose combination 
bictegravir/emtricitabine/tenofovir alafenamide  taken one pill once daily oral treatment.  
6.2 Method of Assignment to Study Intervention  
This is an open- label one-arm study.  
6.3 Study Drug, Materials, and Supplies  
6.3.1 Formulation, Packaging, and Labeling  
Bictegravir 50 mg/Emtricitabine 200 mg/Tenofovir alafenamide 25 mg tablets are capsule -
shaped, film- coated purplish -brown, debossed with "GSI" on one side of the tablet and "9883" 
on the other side of the table t. Each tablet core contains 50 mg of bictegravir, 200 mg of 
emtricitabine, and 25 mg of tenofovir alafenamide. In addition to the active ingredients, the B/F/TAF tablets contain croscarmellose sodium, magnesium stearate, and microcrystalline 
BEST -HBV Protocol Version 4.0: March  16, 202 1  36 
 cellulose. Th e tablet cores are film- coated with iron oxide red, iron oxide black, polyethylene 
glycol, polyvinyl alcohol, talc, and titanium dioxide.  
The B/F/TAF tablets are packaged in white, high -density  polyethylene (HDPE) bottles.  Each 
bottle contains 30 tablets,  silica gel desiccant, and polyester packing material.  Each bottle is 
enclosed with a white, continuous thread, child -resistant polypropylene screw cap with an 
induction -sealed and aluminum -faced liner.  
6.3.2 Storage Handling and Preparation  
Study drugs should be stored at room temperature of 25oC (77oF); excursions are permitted 
between 15oC and 30oC (59oF and 86oF).  Storage conditions are specified on the label.  Until 
dispensed to the subjects, all bottles of study drugs will be stored in a securely locked a rea, 
accessible only to authorized site personnel.  
To ensure the stability and proper identification, study drug(s) will not be stored in a container 
other than the container in which they were supplied.  
Bottles will be relabeled by the Investigational Pharmacist as prescribed to each study subject 
after consent is given and subjects are found to be eligible.  
Consideration should be given to handling, preparation, and disposal through measures that 
will minimize drug contact with the body.  Appropriate prec autions should be followed to avoid 
direct eye contact or exposure through inhalation when handling.  
6.3.3 Final Disposition of Clinical Supplies  
At the end of the study, final study drug supply and accountability records will be reconciled as to drug shipped, d rug consumed, and drug remaining.  Any discrepancies noted will be 
documented.  
Subject accountability for study drug will be ensured through subject interview (during visits), 
diaries, and study drug reconciliation at selected visits before dispensing drug  supply for the 
next visit interval.  At certain clinic visits, subjects will be asked to return any unused study drug 
to the study site.  Final drug accountability reconciliation will be performed at the subject visit 
occurring at the end of therapy or at early discontinuation.  Unused study drug will be 
destroyed.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  37 
 6.4 Dosage Administration  
Subjects will be instructed to take study drug (1 tablet of B/F/TAF) orally with at least 8 ounces 
of plain water once daily in the morning throughout the treatment period.  On Day 1, the first 
dose of the study medication will be administered in clinic after baseline labs have been drawn.  
Following initial dosing at Day 1, the study team will provide the subject the remainder of the 
30-day study supply  to continue on the following day.  Subjects will receive additional 30 -day 
supply on Week 4 and Week 8 visits, and 90 -day supply on Week 12, 24, and 36 visits.  
The study team will be responsible for explaining the correct use of the study drug to the 
subject, verifying that the instructions are followed properly, maintaining accurate records of 
study drug dispensing, and collection of all used study drug, including empty drug packaging.  
Subjects will be instructed to contact the investigator as soon as possible if a complaint or problem with the study drug exists, so that the situation can be assessed in a timely manner.  
6.5 Blinding  
This is an open- label noncomparative study.  Both the subject and study personnel with direct 
contact with the subject will know the study treat ment that is administered.  
6.6 Concomitant Medications  
Drug interaction studies have been conducted with B/F/TAF or its components.  A complete 
summary of the pharmacokinetic effects of other drugs on B/F/TAF or its components are 
found in the BIKTARVY® packag e Insert ( Biktarvy 2018 ).   
Bictegravir is a substrate of CYP3A and UGT1A1.  BIC is also an inhibitor of the organic 
transporter 2 ( OCT2 ) and multidrug and toxin extrusion transporter 1 ( MATE1 ) in vitro, such 
that coadministration of BIC with drugs that ar e substrate of OCT2 and MATE1 (e.g. dofetilide) 
may increase their plasma concentration .  On the other hand, TAF is a substrate of P -
glycoprotein ( P-gp) and breast cancer resistance protein ( BCRP ), thus, coadministration of drugs 
that inhibit these enzymes  may increase the absorption and plasma concentration of TAF.   TAF 
is not an inhibitor of drug transporters P -gp, BCRP, renal transporter MATE1 or OCT2.  At 
clinically relevant concentrations, both BIC and TAF are not an inhibitor of hepatic transporters 
OATP1B1, OATP1B3, OCT1, BSEP, renal transporters OAT1, OAT3, or CYP (including CYP3A) or 
UGT1A1 enzymes.   A list of prohibited medications are listed in Table 6 -1. 
 
BEST -HBV Protocol Version 4.0: March  16, 202 1  38 
 Table 6 -1: List of Prohibited Medications  
Drug Class  Prohibited Agents# 
Antiarrhythmic Agent  Dofetilide  
Anticonvulsants  Phenobarbital, Phenytoin, Carbamazepine, Oxcarbamazepine  
Antimycobacterials  Rifampin, Rifapentine  
GI Motility Agents  Cisapride  
Herbal/Natural Supplements  St. John’s Wort, Echinacea  
Miscellaneous Agents  Mitotane  
# Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the 
duration of the study.  
 
7 ADVERSE  EVENT  AND  TOXICITY  MANAGEMENT  
7.1 Adverse Events  
7.1.1 Definition  of AE  
An adverse event (AE) will be defined as any new unfavorable or unintended sign, symptom, or 
disease, or change of an existing condition, which occurs during or after treatment, whether or 
not considered treatment -related.  If clinically significant laborat ory value lead to or are 
associated with clinical symptom(s), the diagnosis should be reported as an AE.  The lack of 
drug effect is not any AE in clinical trials because the purpose of the clinical trial is to establish 
drug effect.  
An AE does not include  the following:  
 Medical or surgical procedure such as surgery, endoscopy, tooth extraction, and transfusion.  The condition that led to the pr ocedure may be an AE and must be reported.  
 Pre-existing disease, condition, or laboratory abnormalities present or  detected before the 
screening visit that do not worsen.  
 Situations where an untoward medical occurrence has not occurred (e.g. hospitalization for 
elective surgery, social, and/or convenience admissions) . 
 Overdose without clinical sequelae . 
 Any medical condition or clinically significant laboratory abnormality with an onset date before the consent form is signed and not related to a protocol -associated procedure is not 
BEST -HBV Protocol Version 4.0: March  16, 202 1  39 
 an AE.  Such condition or abnormality  is considered a  pre-existing and sho uld be 
documented on the medical history in the CRF.  
Prior to enrollment, study personnel will note the occurrence and nature of each subject’s 
medical condition(s) in the Medical History section  of the CRF.  During the remainder of the 
study, study person nel will again note any change in the condition(s) and the occurrence and 
nature of any adverse events.  
If a subject experiences an AE after the Informed Consent document is signed (entry) but the 
subject is never assigned to treatment (enrollment), the ev ent will only be reported if the 
investigator believes that the event may have been caused by a protocol procedure.  
Adverse event information will be collected from the time subject signs the informed consent 
and until the end of the subject’s study partic ipation, i.e. Study Week 48 (end- of-study visit) or 
earlier if consent has been withdrawn.  All AEs occurring after the subject has entered the study (that is, after the Informed Consent document is signed) must be recorded in the CRF.  If the 
study drug i s discontinued for a subject, study personnel must report and clearly document the 
circumstances and data leading to any such discontinuation, using designated CRFs.  For AEs, 
the subject should be followed until the event resolves or stabilizes, with frequency of follow -
up at the discretion of the investigator.  
In case the investigator notices an unanticipated benefit to the subject, study personnel should enter “unexpected benefit” with the actual event term (for example, the complete actual term 
would be  “unexpected benefit –  sleeping longer”).  
Cases of pregnancy that occur during maternal or paternal exposures to study drug should be reported for tracking purposes.  Data on fetal outcome and breastfeeding are collected for 
regulatory reporting and drug s afety evaluation.  
7.1.2 Reporting Procedures for All Adverse Events  
The investigators are responsible for monitoring the safety of subjects who have entered this 
study and noting any event that seems unusual, even if this event may be considered an 
unanticipate d benefit to the subject.  The investigator is responsible for appropriate medical 
care of subjects during the study.  
The investigator remains responsible for following, through an appropriate health care option, 
AEs that are serious or that causes the sub ject to discontinue the study.  The subject should be 
followed until the event is resolved or explai ned.  Frequency of follow- up will be left to 
discretion of the investigator.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  40 
 7.1.3 Adverse Events Severity  
The Division of AIDS (DAIDS) Table for  “Grading the Severity of Adult and Pediatric Adverse 
Events” corrected version 2.1 ( July 2017) will be used to assess and grade AE severity, including 
laboratory abnormalities judged to be clinically significant.  If the experience is not covered in 
the DAIDS criteria, th e following guidelines should be used to grade severit y: 
 Mild (grade 1):  Mild symptoms causing no or minimal interference with usual social and 
functional activities with intervention not indicated.  
 Moderate (grade 2):  Moderate symptoms causing greater than minimal interference with 
usual social and functional activities with  intervention indicate.  
 Severe (grade 3):  Severe symptoms causing inability to perform usual social and functional 
activities with intervention or hospitalization indicated.  
 Life-threatening (grade 4):  Potentially life -threatening symptoms causing inabil ity to 
perform basic self -care functions with intervention indicated to prevent permanent 
impairment, persistent disability, or death.  
The term “severe” is a measure of intensity and a severe AE is not necessarily serious.  
7.1.4 Adverse Event Relationship to St udy Drug  
The investigator or qualified subinvestigator is responsible for assessing the relationship to 
study drug therapy using clinical judgment and the following considerations:  
 Yes (reasonably related) : There is reasonable possibility that the event ma y have been 
caused by the study drug.  
 No (not related) : Evidence exist that the adverse event has an etiology other than the study 
drug.  For SAEs, an alternative causality must be provider ( e.g., pre -existing condition, 
underlying disease, intercurrent illness, or concomitant medication).  
Ineffective treatment should not be considered as causally related in the context of adverse 
event reporting.  
7.1.5 Adverse Event Expectedness  
The investigator will be responsible for determining whether an adverse event is expected or 
unexpected.  An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the study 
intervention.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  41 
 7.2 Serious Adverse Events  
7.2.1 Definition of SAE  
A serious adverse event (SAE) is defined as an AE that suggests a significant hazard or side 
effects, regardless of the relationship to study drug.  An SAE includes, but may not be limited to, any event that:  
 Results in Death . 
 Is life threatening .  This definition i mplies that the subject, in the view of the investigator, is 
at immediate risk of death from the event.  It does not include an event that, had it 
occurred in a more serious form, might have caused death.  
 Requires in patient hospitalization or prolongation of existing hospitalization.  
 Results in p ersistent or significant disability/incapacity . 
 Results in  congenital anomaly or birth defect . 
Medical and scientific judgment will be exercised in deciding whether classification of an AE as 
serious is appropriate in other situations, such as important medical events that may not be 
immediately life threatening  or result in death or hospitalization , but may jeopardize the 
subject or require intervention to prevent one of the outcomes listed in the definition above.  Examples of medically important events include intensive treatment in an emergency room or 
at home for allergic bronchospasms; development of drug dependency or drug abuse.  Infections resulting from contaminated medicinal product will be considered a medically 
important event.  
7.2.2 Reporting of SAE  
All SAE will be reported to the IRB per i nstitutional guidelines.  SAEs (regardless of relationshi p) 
must be reported to Gilead Pharmacovigilance and Epidemiology (PVE)  Office within fifteen 
(15) calendar  days of first becoming aware of the event.  In turn, the study sponsor will be 
responsible for reporting any unexpected fatal or life -threatening suspected adverse reactions 
to the Division of Antiviral Agents at the FDA no later than seven (7)  calendar d ays after receipt 
of the information.  Safety reporting to the FDA will be done within the reporting requirement 
under 21 CFR 312.32.  
The Gilead PVE  Office  will be notified via fax or email of any potential safety issues or any 
protocol amendments or chang es to the informed consent arising from a safety concern 
associated with any Gilead products within fifteen (15)  days  of first becoming aware of such 
event.  Except for periodic safety reports, copies of all reports submitted to government 
agencies that are related to the study , as well as any correspondence with any such authorities 
will be provided to Gilead Sciences.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  42 
 Contact information:   
Gilead Sciences  Inc., Pharmacovigilance and Epidemiology  (PVE)  
333 Lakeside Drive, Foster City, CA 94404  
Fax: (650) 522 -5477  
Tel: (650) 522- 5114  
Email: Safety_FC@gilead.com  
 
7.3 Laboratory Tests  
Clinical laboratory tests will be performed at the time specified in the Study Schedule (see 
Section 12: Schedule of Activities).  All clinical laboratory assessmen ts will be analyzed through 
a designated laboratory.  
The investigator must further evaluate laboratory values that fall outside a clinically accepted reference range or values that differ significantly from previous values .  Investigators must also 
document their review of each laboratory report by signing or initialing and dating each report.  
Clinically significant laboratory abnormalities will be reported as AEs.  
7.4 Reporting of Events to Pa rticipants  
Any adverse event or serious adverse event that affects the risk/benefit ratio to subjects will 
prompt a revision to the informed consent document.  All subjects will be notified of the 
additional risk and re -consented at their next visit, or earlier if the situation requires.  
7.5 Reporting of Pregnancy  
Pregnancy itself is not an adverse event.  However, complications of pregnancies are AEs and 
may be SAEs.  Pertinent obstetrical information of all pregnancies will be reported to the Gilead 
PVE via fax or email within fifteen (15) calendar  days  from site awareness of the pregnancy.  .  
The participant will be advised to notify her obstetri cian of study agent exposure.   
Pregnancy outcome data (e.g., delivery outcome, spontaneous, or elective termination of the pregnancy, presence of absence of birth defects, congenital abnormalities, or other complications) will be reported to the Gilead PVE  Office within fifteen (15) calendar  days  of the 
site awareness on a protocol -specified form.   
BEST -HBV Protocol Version 4.0: March  16, 202 1  43 
 7.6 Toxicity Management  
All clinical and clinically significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix  C as outlined below.  
 Clinical events and clinically significant laboratory abnormalities will be grade d according to 
the Division of AIDS (DAIDS) Table for “Grading the Severity of Adult and Pediatric 
Adverse Events” corrected version 2.1 (July 2017).    
 Grade 3 and 4 laboratory abnormalities that are found to be clinically significant should be 
confirmed by a repeat testing within 3 calendar days  of awareness of the results and before 
study drug discontinuation, unless such a delay is not consistent with good medical practice.  
7.6.1 Grade 1 and 2 Laboratory Abnormality or Clinical Event  
 Continue study drug at the discretion of the Investigator.  
7.6.2 Grade 3 Laboratory Abnormality or Clinical Event  
 For Grade 3 clinical AE or clinically significant laboratory abnormality that is considered unrelated to the study drug, the study drug may be continued.  
 For Grade 3 clinical AE or clinically significant laboratory abnormality that is considered to be related to study drug  confirmed by repeat test, the study drug should be withheld until 
the toxi city returns to ≤ Grade 2.   
 When restarting study drug following resolution of the adverse event, the study drug should be restarted at full dose.  
 If a laboratory abnormality recurs to ≥ Grade 3 following rechallenge with study drug and is 
considered relat ed to the study drug, then the study drug should be permanently 
discontinue d and the subject managed according to local standard of care practice.  
Recurrence of laboratory abnormalities considered unrelated to study drug may not require 
permanent disconti nuation and study drug may be continued according to the discretion of 
the Investigator.  
7.6.3 Grade 4  Laboratory Abnormality or Clinical Event  
 For Grade 4 clinical AE or clinically significant laboratory abnormality confirmed by repeat 
testing that is considere d related to the study drug, the study drug should be permanently 
discontinue d and subject managed according to local standard of care practice.  The subject 
should be followed as clinically indicated until the  laboratory abnormality returns to 
baseline or  is otherwise explained, whichever occurs first.  Clinically significant Grade 4 
laboratory abnormality that is not confirmed  by repeat testing should be management 
according to the algorithm for the new toxicity grade.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  44 
  Study drug may be continued without dose interruption for a clinically non- significant Grade 
4 laboratory abnormality ( e.g., Grade 4 triglyceride elevation that is nonfasting or that can 
be medically managed) or a clinical event considered unrelated to study drug.  
7.6.4 On-Treatment ALT Fl are and Exacerbation of Hepatitis B Management  
On-treatment ALT flare is defined as:  
 Confirmed (within 3 days of awareness of initial laboratory results) serum ALT > 2 x Day 1 
value and >10 x ULN, with or without associated symptoms . 
7.6.4.1  Management of ALT Flar e in Subjects Receiving Study Medications  
If laboratory results indicate elevation of ALT > 2 x Day 1 value and > 10 x ULN, the following is 
recommended:  
 Schedule the subject to return to the clinic as soon as possible (ideally within 3 days 
after initial laboratory results were drawn) .  During the visit, a clinical assessment of the 
subject will be performed.  The assessment should include a physical examination and 
evaluation of the subject’s mental status.   
 If the ALT elevation is confirmed, check labs for plasma HBV DNA reflex to genotype and 
drug resistance testing, HBV  serology, HDV, HAV IgM, and HCV . 
Recommend to check the following laboratory parameters: serum ALT and AST, total bilirubin, 
INR, and serum albumin.  Based on the results of the confirm atory tests, the following 
treatment modifications are recommended:  
If Normal or Stable  Total Bilirubin or INR  related to Day 1 Liver Function Test 
If ALT levels are elevated (i.e., >2 x Day 1 and >10 x ULN) with normal or stable total bilirubin and INR re lated to Day 1, the subject may remain on study medication and should be 
monitored weekly until ALT levels return to normal or Day 1 level.  During monitoring, if the ALT 
values remain persistently elevated, the Investigator has the discretion based on clinical 
judgment w hether  to withhold study drug or not.  
If Elevated Total Bilirubin or INR  related to Day 1 Liver Function Test  
If ALT levels are elevated (i.e., >2 x Day 1 and >10 x ULN), with total bilirubin confirmed to be 2 x Day 1 value, and INR level is 0.5 above Day 1, provided both are >ULN, the Investigator should 
consider discontinuing study medication (unless the safety of the patient is of immediate concern).  The subject should be monitored weekly as long as ALT, total bilirubin, and INR 
values remain elevated or above Day 1 values.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  45 
 During monitoring, if the ALT values and the liver function tests remain persistently elevated, 
and no alternative cause other than the study drug has been found, the Investigator should 
discuss with a member of the Sa fety Monitoring Committee whether the study drug should be 
discontinued.  
7.6.4.2  Management of Exacerbation of Hepatitis B in Subjects who have Discontinued 
Study Medication  
If laboratory results indicate (1) an ALT elevation >2 x Day 1 and >10 x ULN alone OR associated with (2) abnormal laboratory parameters suggestive of worsening hepatic function (total 
bilirubin >2 x Day 1, INR >0.5 above Day 1, provide d both are > ULN) and the subject is on no 
post -study therapy for HBV, the following is recommended:  
 Sched ule the subject to return to the clinic as soon as possible (ideally no later than 3 
days after the initial laboratory values were drawn).  During the visit, perform a clinical assessment of the subject.  
 Check the following laboratory parameters: serum ALT  and AST, bilirubin, INR, and 
albumin.  
 If the ALT elevation is confirmed, check labs for plasma HBV DNA reflex to genotype and 
drug resistance testing, HBV serology (HBsAg and HBsAb), HDV, HAV IgM, and HCV.  If 
serum HBV DNA is increasing, the Investigator  should consider immediate initiation of 
approved HBV therapy.  
 The subject should be followed until laboratory parameters (ALT, total bilirubin, INR) return to normal or Day 1 up to a maximum of 6 months after the initial occurrence of 
the event.  
7.6.5 On-Treatm ent Hepatitis C Management  
If a subject tests positive for HCV RNA at screening or develops signs or symptoms of active 
hepatitis C, Sponsor recommends that local medical practice be  followed at the discretion of 
the Investigator.  Study medications may be  continued without dose interruption.  Should 
subject’s primary treating physician or the Investigator decide to initiate hepatitis C treatment, drug -drug interaction should be evaluated.  Subject should return to the clinic for scheduled or 
unscheduled fo llow up visit(s) according to local medical practice for laboratory evaluation.  
7.6.6 On-Treatment Hepatitis D Management  
If a subject tests  positive for HDV at screening or develops signs or symptoms of active hepatitis 
D, Sponsor recommends that local medical practice be  followed at the discretion of the 
Investigator.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  46 
 8 QUALITY  CONTROL  AND  QUALITY  ASSURANCE  
This study will be conducted in acco rdance with International Conference on Harmonisation 
Good Clinical Practice (ICH GCP) and the U.S. Code of Federal Regulations (CFR) applicable to 
clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR 
Part 812).  
The investigator agrees to be responsible for implementing and maintaining quality control and quality assurance systems to ensure that trials are conducted and data are generated, documented, and reported in compliance with the protocol, accepted standards of GCP, and all 
applicable federal, state, and local laws, rules and regulations relating to the conduct of the 
clinical study.  
The investigator also agrees to conduct the study in an efficient and diligent manner and in conformance with this protocol; g enerally accepted standard of GCP; and all applicable federal, 
state, and local laws, rules and regulations relating to the conduct of the clinical study.  
The investigator must allow study -related monitoring, audits, and inspection by the IRB, 
sponsor (or designee), government regulatory agencies, and, if applicable, University 
compliance and quality assurance groups of all trial- related documents and procedures.   
The investigator shall prepare and maintain accurate study documentation in compliance with GCP standards and applicable federal, state, and local laws, rules and regulations.  
The IHV Clinical Research Unit (C RU) will perform internal quality management of study 
conduct, data and biological specimen  collection, documentation and completion.  An 
individualized quality ma nagement plan will be developed.  
Quality control ( QC) procedures will be implemented beginning with the data entry system and 
data QC checks that will be run on the database will be generated. Any missing data or data 
anomalies will  be addressed.  
 
BEST -HBV Protocol Version 4.0: March  16, 202 1  47 
 9 STATISTICAL  CONSIDERATIONS  
9.1 General Consideration & Populations for Analyses  
The primary analysis for efficacy analyses will employ intention -to-treat (ITT) population 
defined as the full analysis population, which will include all subjects who have received at least 
1 dose of the study drug.   
The secondary analysis for efficacy analyses will employ a per- protocol (PP) population, which 
will include all subjects who have received at least one  dose of the study drug, and have not 
committed any major protocol violation, including the violation of key eligibility criteria.  In the 
Wee k 24 (or Week 48) per-protocol analysis, subjects meeting any of the following criteria will 
be excluded:  
a. Subjects who do not have on -treatment HIV -1 RNA and/or HBV DNA in the Week 24 (or 
Week 48) analysis window, except when missing data is due to discontinuation of study 
drug for lack of efficacy.  
b. Subjects who were removed from study due to nonadherence to study drug or due to 
protocol violation by the subject.  
9.2 Sam ple Size Determination  
This study is anticipated to screen up to 75 subjects to enroll appro ximately 60 subjects 
coinfected with HIV and HBV , who are currently on antiretroviral therapy.  The primary analysis 
endpoint to evaluate treatment efficacy used to compute the sample size is the observed HIV -1 
viral suppression rate.  A true suppression r ate at Week 24 of at least 91% would be considered 
active in this patient population.  An exact binomial test with a 0.05 type I error rate will have 
84% power to detect the difference between the null hypothesis proportion (number of suppressed/total number treated) of 0.773 (based on published results) and the research 
hypothesis proportion of 0.910 (our educated guess on the desired rate of success) when the 
sample size is 6 0.  
 
9.2.1 Analysis Objectives  
The primary objective of this study is to evaluate the efficacy of FDC B/F/TAF in adults 
coinfected with both HIV -1 and HBV , after switching from their current antiretroviral regimen, 
as determined by HIV -1 RNA <50 copies/mL and/or HBV DNA <29 IU/mL at Wee k 24.   
The secondary objectives of the study include evaluation of HIV -1 and HBV  viral suppression at 
Week 48 as well as safety and tolerability at Week 24 and Week 48.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  48 
 9.2.2  Analysis of the Primary Efficacy Endpoints  
The primary endpoints are:  
 The proportion of subjects with HIV -1 RNA <50 copies/mL at Week 24 as defined by the US 
FDA Snapshot Algorithm.  
 The proportion of subjects with plasma HBV DNA <29 IU/mL at Week 24 using the missing = 
failure method.  
9.2.2.1  US FDA Snapshot Algorithm  for HIV -1 Efficacy Analyses  
The analysis window at Week 24 is defined as from Study Day 140 to Day 196.  All HIV -1 RNA 
data collected on- treatment will be used in the snapshot algorithm.  HIV -1 Virologic outcome 
will be defined as the following categories:  
 HIV- 1 Virologic Success:  this includes subject who have the last available HIV -1 RNA <  50 
copies/mL in the Week 24 analysis window while on study treatment.  
 HIV- 1 Virologic Failure: this includes subjects who  
a. Have the last available HIV -1 RNA ≥  50 copies/mL in the Week 24 analysis window 
while on study treatment, or  
b. Do not have on -treatment HIV -1 RNA data in the Week 24 analysis window and  
1) Discontinue study drug prior to or in the Week 24 analysis window due to 
lack of efficacy, or  
2) Discontinue study drug prior to or in the Week 24 an alysis window due to 
reasons other than adverse events (AE), death, or lack of efficacy and have 
the last available HIV -1 RNA up to 1 day after the premature discontinuation 
of the study drug ≥  50 copies/mL.  
 No HIV- 1 Virologic Data in the Week 24 analysis window:  this includes subjects who do not 
have on -treatment HIV -1 RNA data in the Week 24 analysis window because of the 
following:  
a. Discontinuation of the study drug prior to or in the Week 24 analysis window due to 
AE or death (regardless of  whether the l ast available HIV -1 RNA up to 1 day after the 
premature discontinuation of the study drug <  50 copies/mL or not), or  
b. Discontinuation of the study drug prior to or in the Week 24 analysis window due to reasons other than AE, death, or lack of efficacy (e.g. , withdrew consent and loss to 
follow -up) and the last available HIV -1 RNA up to 1 day after the premature 
discontinuation of the study drug is <  50 copies/mL, or  
c. Missing data during the window but remains on study drug.  
 
BEST -HBV Protocol Version 4.0: March  16, 202 1  49 
 9.2.2.2  Missing = Failure Method  for HBV Efficacy Analyse s 
Similarly,  the analysis window at Week 24 for HBV DNA outcomes is defined as from Study Day 
140 to Day 196.  For HBV DNA analysis, this study will use the missing = failure method.  HBV 
virologic outcome will be defined as follow s: 
 HBV Virologic Success:  this includes subject who have the last available HBV DNA <29 IU/mL 
in the Week 24 analysis window while on study treatment.  
 HBV Virologic Failure: this includes subjects who  
a. Have the last available HBV DNA ≥  29 IU/mL in the Week 24 analysis window while 
on study treatment, or  
b. Do not have on -treatment HBV DNA data in the Week 24 analysis window regardless 
of reason  (e.g. discontinued study drug due to AE, death or lack of efficacy; missed 
Week 24 visit; withdrew consent for an y reason) . 
9.2.3 Analysis of the Secondary Endpoints  
The secondary endpoints include:  
 The proportion of subjects with HIV -1 RNA <  50 copies/mL at Week 48 as defined by the US 
FDA Snapshot Algorithm.  
 The proportion of subjects with plasma HBV DNA <  29 IU/mL at We ek 48 using the missing = 
failure method.  
 Change from baseline in CD4 cell count and percentage at Week 24 and at 48.  
 Proportion of subjects with normalized ALT at Week 24 and Week 48.  
 Proportion of subjects with HBV  e antigen (HBeAg) loss and seroconversion to anti -HBe at 
Week 24 and Week 48.  
 Proportion of subjects with HBV  surface antigen (HBsAg) loss and seroconversion to anti-
HBs at Week 24 and Week 48.  
 Change from baseline in Fibroscan test score at Week 24 and Week 48.  
9.2.4 Safety Analyses  
All safety analy sis will be performed using the intention- to-treat population.  All safety data 
collected on or after the date,  that the study drug was first administered up to the end of the 
subject’s study participation will be summarized for the subject in the safety a nalysis.  
The primary safety endpoint is the proportion of subjects who discontinues study drug due to 
an adverse event.  
There is no formal stopping rule for this trial.  The toxicity data will be monitored closely 
through the therapy.  Addressing the safet y of FDC B/F/TAF, a maximum width 95% confidence 
BEST -HBV Protocol Version 4.0: March  16, 202 1  50 
 interval (CI) for any adverse event, grade 3 or higher t oxicity will be about 28%.  For 5 0 patients 
on the study, if the true unknown probability of a rare toxicity is 0.05 (5%), the probability of 
observing  one or more toxicities is 0.92 (92%), and for  3% true toxicity rate, it is 78 %.  
9.2.5 Baseline Descriptive Statistics  
Demographics and other baseline characteristics will be summarized by treatment group.  
9.2.6 Planned Interim Analyses  
No interim analyses are planned for this study.  
9.2.7 Subgroup Analyses  
For subgroup analyses, the analysis of the efficacy endpoints  will be performed and stratified 
based on age group, sex, race,  baseline CD4 count, HBV DNA viral load, baseline HBeAg status, 
and baseline HBsAg level .  
9.2.8 Exploratory Analyses  
Exploratory analyses will include assessment of changes in quantitative HBsAg and immune 
activation markers during study drug treatment.  Immune markers includes plasma hsCRP, IL -6, 
TNF-α, and D -dimer and cellular HLA- DR+CD38+ CD4 and CD8 T lymphocytes .  The exploratory 
analyses will determine group difference in the exploratory endpoints from baseline (Day 1) to Week 24 and Week 48 time points using a paired t- test.  All inferential tests will be indicated 
statistical significance wi th a P -value of less than 0.05 (two -sided).  
 
     
BEST -HBV Protocol Version 4.0: March  16, 202 1  51 
 10 ADMINISTRATIVE,  ETHICAL,  AND  REGULATORY  CONSIDERATIONS  
10.1 Informed Consent Process  
Informed consent is a process that is initiated prior to the individual agreeing to participate in 
the study and continues thr oughout the individual’s study participation.   The informed consent 
form will be IRB-approved and the participant will be asked to read and review the document.  
The investigator is responsible for presenting the risks and benefits of study participation to the 
subject in simple terms using  the informed consent document.  The investigator will ensure that 
written informed consent is obtained from each subject or legally authorized representative by 
obtaining the appropriate signatures and dates on the informed consent document before the 
performance of protocol evaluations or procedures.   
Participants must be informed that participation is voluntary and that they may withdraw from 
the study at any time, without prejudice.  Copies of the inform ed consent documents will be 
given to the participants for their records. The informed consent process will be conducted and 
documented in the source document (including the date), and the screening form signed, 
before the participant undergoes any study -specific procedures. The rights and welfare of the 
participants will be protected by emphasizing to them that the quality of their medical care will 
not be adversely affected if they decline to participate in this study.  
Additionally, employees or students will be made aware that employment status or academic 
standing will not be affected by your participation or non -participation in this study.  Students 
or employees will not be consented by anyone in a supervisory role.  
As the majority of the patient popul ations from which the study participants are drawn are 
literate, written informed consent will typically be  provided during the informed consent 
process .  However, oral consent will be obtained for illiterate participants as consistent with 
UMB IRB Policy without separate IRB approval for each specific use.  At Continuing Reviews, the 
UMB IRB will be informed of the number of illiterate participants who provided consent 
verbally.  A non -study team witness will be present for the oral consenting process.  
10.2 Study Discontinuation and Closure  
This study may be suspended or prematurely terminated if there is sufficient reasonable cause.  
The suspending or terminating party will provide written notification, documenting the reason 
for study suspension or termination,  to the study participants, investigator, funding agency, the 
Investigational New Drug (IND) sponsor , and regulatory authorities  in a timely manner.  If the 
study is prematurely terminated or suspended, the Investigator  will promptly inform stu dy 
BEST -HBV Protocol Version 4.0: March  16, 202 1  52 
 participants, the IRB , and sponsor , and he will provide the reason(s) for the termination or 
suspension.  Study participants will be contacted, as applicable, and be informed of changes to 
study visit schedule.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stopping    
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
Study may resume once concerns about safety, protocol compliance, and data quality are 
addressed, and satisfy the sponsor, DSMB , IRB  and/or Food and Drug Administration (FDA) as 
appropriate.  
10.3 Confidentiality and Privacy  
Participant confidentiality and privacy is strictly held in trust by the participating investigators, their staff, and the sponsor. This confidentiality is extended to c over testing of biological 
samples and genetic tests in addition to the clinical information relating to participants.  
Therefore, the study protocol, documentation, data, and all other information generated will be 
held in strict confidence. No information concerning the study or the data will be released to 
any unauthorized third party without prior written approval of the sponsor.  
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representa tives of the sponsor, representatives of the IRB , 
regulatory agencies or pharmaceutical company supplying study product may inspect all 
documents and records required to be maintained by the investigator, including but not limited 
to, medical records (office, clinic, or hospital) and pharmacy records for the participants in this 
study. The clinical study site will permit access to such records.  
The study participant’s contact information will be securely stored at each clinical site for 
internal use during the study. At the end of the study, all records will continue to be kept in a 
secure location for as long a period as dictated by the reviewing IRB, Institutional policies, or sponsor requirements.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  53 
 Study participant research data, which is for purposes of statistical analysis and scientific 
reporti ng, will be entered into the electronic  database for future analysis.  This will not include 
the participant’s contact or identifying information. Rather, individual participants and their research data will be id entified by a unique study identification number. The study data entry 
and study management systems used by the IHV research staff will be secured and password protected. At the end of the study, all study databases will be de -identified and archived at th e 
IHV. 
10.4 Future Use of Stored Specimens and Data  
Data collected for this study will be analyzed and stored at University of Maryland, Institute of 
Human Virology.  With the participant’s approval within the consent and as approved by local 
IRB, de-identified biological samples may be shared with Gilead Sciences, Inc.  with the goal of 
sharing of data.  These samples could be used to research immune response to HBV , its 
complications and other conditions for which individuals with HBV  are at increased risk, and to 
improve treatment.  Gilead Sciences, Inc. will also be provided with a code -link that will allow 
linking the biological specimens with the phenotypic data from each participant, maintaining 
the blinding of the identity of the participant.  
During the conduct of the study, an individual participant can choose to withdraw consent to have optional biological specimens for future research  stored , in which case they will be 
destroyed.   
When the study is  completed , access to study da ta and/or samples will be provided  by Dr. Joel 
Chua.  
10.5 Key Roles and Study Governance  
Principal Investigator  
Joel Chua, MD; Assistant Professor  
University of Maryland,  Institute of Human Virology  
725 W. Lombard Street  
410-706-5704  
JChua@ihv.umaryland.edu  
 
10.6 SAFETY OVERSIGHT  
Safety oversight will be under the direction of a Safety Monitoring Committee (SMC) composed 
of individuals with the appropriate expertise, including experience with the treatment and/or care of those with HIV -1 and HBV .  At least two members of the SMC will be independent from 
BEST -HBV Protocol Version 4.0: March  16, 202 1  54 
 the study conduct and free of conflict of interest, or measures should be in place to minimize 
perceived conflict of interest.  The SMC  will meet at least semiannually to assess safety and 
efficacy data.  The SMC  will provide its input to the study sponsor and Principal Investigator.  
10.7 Clinical Monitoring  
Clinical site monitoring is conducted to ensure that the rights and well- being of trial participants  
are protected, that the reported trial data are accurate, complete, and verifiable, and that the 
conduct of the trial complies  with the currently approved protocol/amendment(s), with ICH 
GCP, and with applicable regulatory requirement(s).  
Monitoring will begin as the first two subjects screen for the clinical trial.  This will entail a 
clinical research nurse providing 100% verification of screening consent and data verification of 
the first 2 subjects.  An independent SMC member will be available for consultation as needed 
for any medical conce rns.  
Once subjects begin enrollment, consent and eligibility verification will continue at 100%, with 15% targeted subject data review.   
10.8 Data Handling and Record Keeping  
10.8.1  Data Collection and Management Responsibilities  
All research data and results will b e recorded using data collection forms.  Source documents 
will support the data collected and will include, but not limited to; clinical findings and 
observations, laboratory and test data, hospital medical records, physician or office charts, 
physician or nursing notes, recorded data from automa ted instruments, x -rays, etc.  Research 
data will be entered into a secure  electronic database.  This electronic database  tracks all data 
corrections made by authorized users, providing audit trails for monitoring or query.  
10.8.2  Study Records Retention  
The investigator is responsible for retaining all essential documents listed in the ICH GCP Guideline.  All essential documentation for all study subjects are  to be maintained by the 
investigators in a secure storage facility for a minimum of 5 years.  The  FDA requires study 
records to be retained for up to 2 years after marketing approval or disapproval (21 CFR 312.62), or until at least 2 years have elapsed since the formal discontinuation of clinical 
development of the investigational agent for a specific indication.  These records are also to be 
maintained in compliance with IRB, state, and federal medical records retention requirements, whichever is longest.   All stored records are to be kept confidential to the extent required by  
federal, state, and lo cal law.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  55 
 10.9 Protocol Deviation  
A protocol deviation is any noncompliance wi th the clinical trial protocol or ICH GCP guidelines . 
The noncompliance may be either on the part of the participant , the I nvestigator, or the study 
staff.  When a protocol deviation b y the Investigator or his study staff occurs , corrective actions 
are to be developed by the site and implemented promptly.  
These practices are consistent with ICH GCP :  
 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
 5.1 Quality Assurance and Quality Control, section 5.1.1  
 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
It is the responsibility of the I nvestigator to use continuous vigilance to identify and report 
deviations that constitute Reportable New Information within 5 working day s of identification 
of the protocol deviation  or as prescribed by  local IRB requirements .  The I nvestigator  is 
responsible for knowing and adhering to the  reviewing IRB requirements . 
10.10  Publication and Data Sharing Policy  
This trial is registered at ClinicalT rials.gov , and results information  from this trial will be 
submitted to ClinicalTrials.gov.   In addition, every attempt will be made to publish results in 
peer -reviewed journals.   
10.11  Conflict of Interest Policy  
The independence of this study from any actual or perceived influence , such as  by the 
pharmaceutical industry , is critical.  T herefore , any actual conflict of interest of persons who 
have a role in the design, conduct, analysis, publication, or any aspect of this trial  will be 
disclosed and managed accordingly .  Furthermore, persons who have a perceived conflict of 
interest will be required to have such conflicts managed in a way that is appropriate to their 
participation in the design and conduct of this trial.   
 
    
BEST -HBV Protocol Version 4.0: March  16, 202 1  56 
 11 REFERENCES  
Andreatta K, Aco sta R, D’Antoni ML, et al. (2019) Sustained viral suppression among 
participants with pre -existing M184V/I who switched to bictegravir/emtricitabine/tenofovir 
alafenamide. In: 17th European AIDS Conference. November 6 -9, 2019, Basel, Switzerland.  
Abstract  PE13/21.  
Antiretroviral Pregnancy Registry Steering Committee. (2018) Antiretroviral pregnancy registry 
interim report for January 1989 through 31 January 2018. Available from URL: 
www.APRegistry.com.  
Agarwal K, Fung SK, Nguyen TT, et al. (2015)  Twenty -eight day safety, antiviral activity, and 
pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.  J 
Hepatol . 62(3):533- 540.  
Biktarvy [U.S. package insert]. Gilead Sciences Inc. Foster City CA. Revised: 2/2018.  
Birkus  G, Bam RA, Frey CR, et al. (2012) Intracellular activation pathways for GS7340 and the 
effect of antiviral protease inhibitors. In: 19th Conference on Retroviruses and Opportunistic 
Infections. Mar 5 -8, 2012, Seattle, WA. Abstract 577.  
Buti M, Gane  E, Seto WK,  et al.  (2016) Tenofovir alafenamide versus tenofovir disoproxil 
fumarate  for the treatment of patie nts with HBeAg -negative chronic hepatitis B virus infection: 
a randomised, double -blind,  phase 3, non- inferiority trial.  Lancet Gastroenterol He patol.  
1(3):196 -206.  
Buti M, Tsai N, Petersen J, et al. (2015) Severe- year efficacy and safety of treatment with 
tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 60(5):1457-
1464.  
Center for Disease Control and Prevention.   (2017) CDC fact sheet: HIV and Viral hepatitis. 
https://www.cdc.gov/hiv/pdf/library/factsheets/hiv -viral- hepatitis.pdf . Accessed 04 Dec 2018 . 
Chan HLY, Fung S, Seto WK , et al. (2016) Tenofovir alafenamide versus tenofovir disoproxil 
fumarate for the treatment of HBeAg  positive chronic hepatitis B virus infection: a randomised, 
double -blind, phase 3, non -inferior ity trial. Lancet Gastroenterol Hepatol. 1(3):185– 195. 
Colin JF, Cazals -Hatem D, Loriot M a, et al. (1999) Influence of human immunodeficiency virus 
infection on chronic hepatitis B in homosexual men. Hepatology . 29:1306 -1310.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  57 
 European Association for the Study of the Liver (EASL). (2017) EASL 2017 clinical practice 
guidelines on the management of hepatitis B virus infection. J Hepatol.  67:370- 398.  
Gallant J, Brunetta J, Crofoot G, et al. (2016) Brief report: Efficacy and safety of switching to a 
single -tablet regimen of elvitegravir/cobicistat/emtricitabine /tenofovir alafenamide in HIV -1/ 
hepatitis B -coinfected adults. J Acquir Immune Defic Syndr . 73(3):294- 298.  
Gallant J, Lazzarin A, Mills A, et al. (2017) Bictegravir, emtricitabine, and tenofovir alafenamide 
versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV -1 infection (GS -US-
380- 1489): a double -blind, multicentre, phase 3, randomised controlled non -inferiority trial. 
Lancet.  390: 2063-2072.  
Hightower K E, Wang R, Deanda F,  et al.  (2011) Dolutegravir (S/GSK1349572) exhibits 
significantly slower dissociation than raltegravir and elvitegravir from wild -type and integrase 
inhibitor -resistant HIV -1 integrase -DNA complexes.  Antimicrob Agent s Chemother . 55(10):4552-
4559.  
Marcellin P, Gane E, Afdhal N, et al. (2013) Regression of cirrhosis during treatment with 
tenofovir disoproxil fumarate for chronic hepatitis B: a 5 -year open -label follow -up study. 
Lancet. 381(9865):468- 475.  
Murakami E, Bab usis D, Wang T, et al. (2013) Efficient hepatic delivery of tenofovir by prodrug 
tenofovir alafenamide in nonclinical studies supports low- dose treatment of hepatitis B virus. 
HepDart 2013. Dec 8 -13, 2013, Hawaii, Hawaii. Abstract 104.  
Rockstroh JK, Sax PE , Daar ES, et al. (2018) High HBV and HIV suppression with treatment of 
HIV/HBV coinfection in B/F/TAF studies. CROI (Boston, MA) Abstract 618, 2018 March 4 -7. 
Session number P -K06.  
Sax PE, Pozniak A, Montes ML, et al. (2017) Coformulated bictegravir, emtricitabine, and 
tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV -1 infection (GS -US-380– 1490): a randomised, double -blind, multicentre, 
phase 3, non -inferiority trial. Lancet . 390:2073 -2082.  
Singh KP, Crane M, Audsley J, et al. (2017) HIV-hepatitis B virus coinfection: epidemi ology, 
pathogenesis, and treatment.  AIDS 31:2035 -2052.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  58 
 Sun HY, Sheng WH, Tsai MS, et al. (2014) Hepatitis B virus coinfection in human 
immunodeficiency virus -infected patients: a review. World J Gastroenterol . 20(40):14598-
14614.  
Thio CL. (2002) HIV-1, hepatitis B virus, and risk of liver- related mortality in the Multicenter 
Cohort Study (MACS). Lanc et. 360(9349):1921- 1926.  
Tsiang M , Jones GS, Goldsmith J,  et al.  (2016) Antivir al activity of Bictegravir (GS- 9883), a novel 
potent HIV -1 integrase strand transfer inhibitor with an improved resistance profile.  
Antimiccrob Agents Chemother. 60(12): 7086 -7097.  
Van Hemert FJ, Berkhout B, Zaaijer HL. (2014) Differential binding of tenofovir and adefovir to 
reverse transcriptase of hepatitis B virus. PLoS One.  9(9): e106324.  
Vemlidy [U.S. package insert]. (2018) Gilead Sciences Inc. Foster City CA.  
While K L, Cihlar T, Miller MD.  (2016) Potent activity of Bictegravir (BIC; GS- 9883), a novel 
unboosted HIV -1 integrase strand transfer inhibitor (INSTI), against patient isolates with INSTI -
resistance. 14th European Workshop on HIV and Hepatitis (Rome, Italy), Ab stract O -01, 2016 
May 25 -27. 
White K L, Niedziela -Majka A, Novikov N, et al. (2017) Bictegravir dissociation half -life from HIV -
1 G140S+Q148H integrase/DNA complexes. CROI (Seattle WA) Abstract 497, 2017  February 13 -
16. Session number P -J3. 
Zheng L., Rosenk ranz SL, Taiwo B., et  al. (2013) The Design of Single -Arm Clinical Trials of 
Combination Antiretroviral Regimens for Treatment -Naïve HIV -Infected Patients. AIDS Res Hum 
Retroviruses . 29(4):652- 657.  
 
   
 
BEST -HBV Protocol Version 4.0: March  16, 202 1  59 
 APPENDIX A.  SCHEDULE OF ACTIVITIES  
Study Procedures  Screening               
(D-90 to - 3) Day 1  Study Week  
4 8 12 24 36 48g 
 Administrative Procedures  
Informed Consent  X               
Inclusion/Exclusion Criteria  X X             
Complete Medical History  X               
Interval Medical History    X X  X  X  X  X X  
Administer 1st Dose of Study Drug    X             
Study Drug and Diary Dispensation    X X X X X X   
Study Drug Accountability      X X X X X X 
 Clinical Procedures/Assessments  
Complete Physical Exam  X X           X 
Targeted Physical Exam, if needed      X X X X X   
Concomitant medication  X X X X X X X X 
Adverse event     X X X X X X X 
Height  X               
Vital Signs (T, P, R, BP) and Wt  X  X X X X X X X 
12-lead ECG  X               
  Clinical Laboratory Tests  
Plasma HIV -1 RNA  Xa X X X X X X X 
Plasma HBV DNA  Xa X X X X X X X 
Quantitative HBsAg level  Xa X X X X X X X 
CD4 Cell Count  Xa X     X X X X 
HBsAg/HBcAb/HBsAb/HBeAg/HBeAb  Xa         X   X 
HIV-1 Genotype/Phenotypeb   X           X 
HBV Resistance Assayc   X           X 
HBV Genotypec   X             
HCV serology  Xa               
HDV serology  Xa               
CBC Xa X X X X X X X 
CMP  Xa X X X X X X X 
Coagulation Tests (PT/PTT)  Xa             X 
Fibroscan (IHV only)    Xe       Xf   Xf 
Urinalysis  Xa               
Urine pregnancy test (if WOCPd)   X X X X X X X 
Serum pregnancy test (if WOCPd) X               
 Research Laboratory Tests  
PAXgene RNA Assay    X     X X X X 
PAXgene DNA Assay    X             
PBMC Storage    X X X X X X X 
Plasma Storage    X X X X X X X 
Serum Storage    X X X X X X X 
 
BEST -HBV Protocol Version 4.0: March  16, 202 1  60 
 Legend:  
a May use outside labs if within 90 days.  
b If HIV -1 RNA is ≥ 500 copies/mL  
c If HBV DNA is ≥ 500 IU/mL  
d Woman of childbearing potential  
e Fibroscan at Baseline (Day 1) may be conducted within 30 days prior to Day 1 Visit.  
f Fibroscan at Week 24 and Week 48, may be conducted 2 weeks before or after the Study Visit.  
g Week 48 (End of Study) Visit procedures w ill be used for Early Termination/Subject Withdrawal Visits.  
 
    
 
      
    
BEST -HBV Protocol Version 4.0: March  16, 202 1  61 
 APPENDIX B.  PROTOCOL AMENDMENT HISTORY  
Version  
(version date)  Affected Sections  Description of Changes  Brief Rationale  
1.1 
 3.2.2. Day 1 
Assessments  Dispense study drug supply 
from 30 -days to up to 60 -days  Allow extra study drug 
to be dispense to 
subjects on Day 1 to avoid having them ran out before next study visit window.  
 
2.0 
 5.3 Exclusion 
Criteria  Clarification on history of 
malignancy as an exclusion  Allow subjects with 
history of malignancy that is in remission to be included in this phase 4 study.  
 
3.0 
 5.2 Inclusion 
Criteria  and Figure 
3-1 in Study 
Schema . Rationale 
in Section 4. Discussion of Design  
 Eligibility to allow those with 
M18V mutation and th ose 
who are currently  not HIV 
suppressed to enter the study.  
 
 Allows subjects with 
M184V  and M184I  
mutation or having HIV 
viral load not suppressed to be 
included in the study as these does not affect 
response to B/F/TAF.   
Rationale added to Section 4. Discussion of Design  
 
4.0 
 
 3.1 Study Design , 
and 3.2 St udy 
Procedures   Change from single center to 
multicenter study . Fibroscan 
will only be done in the IHV.  Allow  addition of a 
second site (Philadelphia 
DOH clinic) . Only IHV 
site has FibroScan to conduct this procedure.  
 
 
    
 
BEST -HBV Protocol Version 4.0: March  16, 202 1  62 
 APPENDIX C.  MANAGEMENT OF CLINICAL & LABORATORY AEs  
 
 
         

BEST -HBV Protocol Version 4.0: March  16, 202 1  63 
 APPENDIX D.  MANAGEMENT OF ON -TREATMENT ALT FLARES  
 
 
 
  
 
 

BEST -HBV Protocol Version 4.0: March  16, 202 1  64 
 APPENDIX E .  DEFINITION OF STAGE 3 OPPORTUNISTIC ILLNESS IN HIV  
Based on CDC Guidelines, Stage 3 HIV/AIDS opportunistic infections are as follows:  
1. Candidiasis of bronchi, trachea, or lungs  
2. Candidiasis of esophagus  
3. Cervical cancer, invasive  
4. Coccidioidomycosis, disseminated or extrapulmonary  
5. Cryptococcosis, extrapulmonary  
6. Cryptosporidiosis, chronic intestinal ( >1 month duration)  
7. Cytomegalovirus disease (other than liver, spleen or nodes)  
8. Cytomegalovirus retinitis (with loss of vision)  
9. Encephalopathy, HIV -related  
10. Herpes simplex: chronic ulcer(s) (> 1 month duration) ; or bronchitis, pneumonitis or 
esophagitis  
11. Histoplasmosis, disseminated or extrapulmonary  
12. Isosporiasis, chronic intestinal ( >1 month duration)  
13. Kaposi’s sarcoma  
14. Lymphoma, Burkitt’s (or equivalent term)  
15. Lymphoma, immunoblastic (or equivalent term)  
16. Lymphoma, primary, of brain  
17. Mycobacterium avium complex or Myobacterium kansasii , disseminated or extrapulmonary  
18. Mycobacterium tuberculosis , of any site, pulmonary, disseminated or extrapulmonary  
19. Mycobacterium , other species or unidentified species, disseminated or extrapulmonary  
20. Pneumocystis jirovecii (previou sly known as Pneumocystis carinii) pneumonia  
21. Pneumonia, recurrent  
22. Progressive multifocal leukoencephalopathy  
23. Salmonella septicemia, recurrent  
24. Toxoplasmosis of br ain 
25. Wasting syndrome attributed to HIV infection  
 
 
BEST -HBV Protocol Version 4.0: March  16, 202 1  65 
 APPENDIX F.  DEFINITION OF  CHILDBEARING POTENTIAL , CONTRACTIVE 
REQUIREMENTS  & PREGNANCY PRECAUTIONS  
Definition of Childbearing Potential  
For the purpose of this study, a female born subject is considered of childbearing potential 
following the initiation of puberty (Tanner stage 2) until becoming post- menopausal, unless 
permanently sterile or with medically documented ovarian failure.  
Women are considered to be in a postmenopausal state when the y are ≥54 years of age with 
cessation of previously occurring menses for ≥12 months without an alternative cause.  In addition, women of any age with amenorrhea of ≥12 months may also be considered 
postmenopausal if their follicle -stimulating  hormone (FSH)  level is in the postmenopausal range 
and they are not using hormonal contraception or hormonal replacement therapy.  
Permanent sterilization includes hysterectomy, bilateral oophorectomy, or bilateral 
salpingectomy in a female subject of any age.  
Contracep tion Requirement for Female Subjects  
a. Study Drug Effect on Pregnancy and Hormonal Contraception  
The effect of  B/F/TAF in pregnancy is  currently not known.  Relevant non- clinical reproductive 
studies for human pregnancy do not indicate a strong suspicion of human teratogenicity or fetal 
toxicity.   Data from clinical pharmacokinetic interaction studies of B/F/TAF have demonstrated 
that there is no reduction in the clinical efficacy of hormonal contraception or that the effect on 
hormonal contraception is insignificant.  Please refer to the latest BIKTARVY U.S. package insert 
for more information.  
b. Study Drug Effect on Pregnancy and Hormonal Contraception  
To be included in the study, women of childbearing potential requires the use of highly effective contraceptive measures.  They must have a negative serum pregnancy test at 
Screening and negative urine pregnancy test on the Day 1 visit prior to enrollment.  At the minimum, a pregnancy test will be performed at the end of relevant systemic exposure.  In the 
event  of a delayed menstrual period (over one month between menstruations), a pregnancy 
test must be performed to rule out pregnancy.  This will apply even to women of childbearing 
potential with infrequent or irregular periods.   
 
BEST -HBV Protocol Version 4.0: March  16, 202 1  66 
 Female subject must agree to at least one of the following from Screening until end of study:  
 Complete abstinence from intercourse of reproductive potential.  Abstinence is an 
acceptable method of contraception only when it is in line with the subject’s preferred 
and usual lifestyle.  
OR 
 Consistent and correct use of 1 of the following methods of birth control:  
− Intrauterine device (IUD) with a failure rate of <1% per year  
− Intrauterine hormone -releasing system (IUS) with a failure rate of <1% per year  
− Tubal sterilization  
− Essure  micro -insert system (provided confirmation of success 3 months after 
procedure  
− Vasectomy in the male partner (provided that the partner is the sole sexual 
partner and had confir mation of surgical success 3 months after procedure)  
OR 
  Consistent and correct use of hormonal method and one barrier method  
− Barrier methods:  
 Diaphragm with spermicide  
 Cervical cap with spermicide  
 Male condom (with or without spermicide)  
− Hormonal methods:  
 Oral contraceptives (either combined or progesterone only)  
 Injectable p rogesterone  
 Implants of levonorgestrel 
 Transdermal contraceptive patch  
 Contraceptive vaginal ring  
 
Contraceptive Requirements for Male Subjects  
Relevant systemic concentrations of the study drug may in theory  be achieved in a female 
partner from exposure o f the male subject’s seminal fluid.  Therefore, male subjects with 
female partners of childbearing potential must abstain from heterosexual intercourse or use 
condoms during treatment and until end of study.  
BEST -HBV Protocol Version 4.0: March  16, 202 1  67 
 Procedures to Follow in the Event of Pregnancy  
Subjects will be instructed to notify the study team if they become pregnant at any time during 
the study.  Subject who become pregnant or who is suspected to be pregnant must report the 
information to the Investigator and after a thorough assessment, the s tudy drug may be 
discontinued based on clinical judgment.  Subjects whose partner has become pregnant or suspects she is pregnant during the study must report the information to the Investigator.  